

1 **Title: Repurposing of Glatiramer Acetate to Treat Heart Diseases**

2 **One Sentence Summary:** Glatiramer acetate promotes reparative processes in rodent models of
3 cardiac injury and reduces the inflammatory process in ADHF patients.

4 **Authors:** Gal Aviel¹, Jacob Elkahal¹, Kfir Baruch Umansky¹, Hanna Bueno-Levy¹, Shoval
5 Miyara¹, Daria Lendengolts¹, Lingling Zhang¹, Zachary Petrover¹, David Kain¹, Tali Shalit²,
6 Rina Aharoni³, Ruth Arnon³, David Mishaly⁴, Uriel Katz^{4,5}, Dean Nachman⁶, Mahdi Ammar⁶,
7 Rabea Asleh⁶, Offer Amir⁶, Eldad Tzahor^{1*}, Rachel Sarig^{1*}

8
9 **Affiliations:**

10 ¹ *The Department of Molecular Cell Biology, Weizmann Institute of Science; Rehovot, Israel.*

11 ² *Bioinformatics unit, G-INCPM, Weizmann Institute of Science; Rehovot, Israel.*

12 ³ *The Department of Immunology and Regenerative Biology, Weizmann Institute of Science,*
13 *Rehovot, Israel.*

14 ⁴ *Pediatric Heart Institute, Edmond and Lily Safra Children's Hospital, Sheba Medical Center,*
15 *Tel Hashomer, Israel.*

16 ⁵ *Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.*

17 ⁶ *Heart Institute, Hadassah Medical Center and Faculty of Medicine, Hebrew University,*
18 *Jerusalem, Israel.*

19
20 * Corresponding authors' email: rachel.sarig@weizmann.ac.il (R.S.);

21 eldad.tzahor@weizmann.ac.il (E.T.)

23 **Abstract:**

24 Myocardial injury may ultimately lead to adverse ventricular remodeling and development
25 of heart failure (HF), which is a major cause of morbidity and mortality worldwide. Given the slow
26 pace and substantial costs of developing new therapeutics, drug repurposing is an attractive
27 alternative. Studies of many organs, including the heart, highlight the importance of the immune
28 system in modulating injury and repair outcomes. Glatiramer-acetate (GA) is an
29 immunomodulatory drug prescribed for patients with multiple sclerosis. Here we report that short-
30 term GA treatment improves cardiac function and reduces scar area in a mouse model of acute
31 myocardial infarction, as well as in a rat model of ischemic HF. We provide both *in vivo* and *in*
32 *vitro* mechanistic evidence indicating that in addition to its immunomodulatory functions, GA
33 exerts beneficial pleiotropic effects, including cardiomyocyte protection and enhanced
34 angiogenesis, mediated partially by extracellular vesicles carrying a pro-reparative cargo. Finally,
35 as GA is a widely used drug with established efficacy and safety history, we conducted a small,
36 prospective, randomized trial to determine its effect on patients admitted to the hospital with acute
37 decompensated HF (ADHF). Strikingly, a short-term add-on administration of GA, resulted in
38 marked reduction in the cytokine surge and NT-proBNP levels, both associated with acute HF
39 exacerbations. Overall, these findings demonstrate the efficacy of GA in attenuating acute
40 myocardial injury and modulating the inflammatory process in animal models and humans and
41 highlight the potential of GA as a future therapy for a myriad of heart diseases.

42

43

44

45

46

47 **Main Text:**

48 **INTRODUCTION**

49 Heart failure (HF) is a leading cause of morbidity and mortality worldwide. While
50 improvements in revascularization techniques and medical care have significantly reduced
51 mortality rates from acute myocardial infarction (MI), the incidence of ischemic cardiomyopathy
52 is increasing ¹. The pathogenesis of HF is intricately related to a chronic inflammatory process,
53 leading to irreversible loss of cardiomyocytes (CMs) ². While a transient inflammation is essential
54 for tissue healing, including cardiac repair ^{3,4}, a maladaptive immune response may contribute to
55 adverse left ventricle (LV) remodeling and development of chronic HF. The idea of using
56 immunomodulatory drugs to ameliorate LV remodeling and improve heart function after acute MI
57 has been tested in several clinical trials which yielded conflicting results⁵.

58 The development of new drugs is a laborious, long-term, and costly process ⁶. Hence,
59 repurposing approved drugs to treat new indications is an appealing strategy for expanding the
60 therapeutic armamentarium to treat patients. Glatiramer acetate (GA) is a synthetic random
61 copolymer composed of four amino acids that has been used for years for the treatment of multiple
62 sclerosis (MS) ⁷. Originally, GA was designed to resemble the autoantigen myelin basic protein
63 and shown to have beneficial effects in animal model of MS, experimental autoimmune
64 encephalomyelitis ⁸, yet multiple studies revealed its broad immunomodulatory and anti-
65 inflammatory mechanism of action, at different levels of both the innate and the adaptive immune
66 responses ^{9,10}. As such, GA binds promiscuously to major histocompatibility complex (MHC)
67 molecules, acting both as an MHC blocker ¹¹ and a T cell receptor antagonist ¹², leading to
68 inhibition of pathological effector functions. GA has also been shown to modulate the properties
69 of dendritic cells and monocytes to preferentially stimulate type 2 helper T (Th2) cell-like

70 responses ¹³, inducing the secretion of anti-inflammatory cytokines ^{14,15} and elevation of T-
71 regulatory cells (Tregs) ¹⁶. GA-induced Th2 cells and Tregs were shown to accumulate in the
72 injury site and secrete *in situ* anti-inflammatory cytokines and growth factors that suppress the
73 inflammation and augment repair processes ^{17,18}. Based on its broad immunomodulatory mode of
74 action, potential applications of GA for additional pathologies were investigated, showing its
75 beneficial effects in prevention of immune rejection ¹⁹, improvement of stem cells engraftment ²⁰,
76 amelioration of inflammatory bowel disease (IBD) ^{21,22}, and repair of liver fibrosis ²³. Due to the
77 immunomodulatory mechanism of action of GA, its efficacy in various pathological systems, and
78 its broad safety profile, we hypothesized that it might mitigate the pathological inflammatory
79 process associated with myocardial injury, thereby preventing its progression, and improving
80 cardiac outcomes.

81 In the present work, we initiated a drug repurposing process of GA for the treatment of
82 heart diseases from the preliminary pre-clinical work in murine models of acute myocardial
83 ischemia to the completion of a phase 2a clinical trial in patients with HF. First, we tested the
84 potential application of GA for improving heart function using murine models of myocardial
85 ischemia. Our data show beneficial pleiotropic effects of GA treatment on the injured heart,
86 manifested by improved cardiac function and reduced scar area in a mouse model of acute MI as
87 well as in a rat model of HF. Examination of GA's mode-of-action revealed that in addition to its
88 known immunomodulatory effects, shown here for the first time in the context of myocardial
89 inflammation, it promoted CM protection from ischemia-induced death, reduced fibrosis and
90 enhanced angiogenesis. Administration of extracellular vesicles (EVs) isolated from GA-treated
91 hearts recapitulated GA's effects in a mouse model of acute MI, suggesting that these beneficial

92 paracrine effects were mediated by EVs. *In vitro* and *ex vivo* assays further supported a paracrine
93 effect of stromal cells on CMs.

94 Next, we proceeded to conduct a small phase 2a, open-label, randomized-controlled
95 clinical trial to assess the potential and safety of GA treatment in patients hospitalized with ADHF.
96 GA therapy added to standard HF therapy resulted in a significant blunting of the cytokine surge
97 associated with ADHF and improvement in HF severity, as represented by a remarkable reduction
98 in the levels of the natriuretic peptide NT-proBNP, compared to standard HF therapy alone.
99 Overall, our data reveal novel protective and reparative effects of GA in rodent models of cardiac
100 ischemia, as well as its safety and beneficial effects in ADHF patients. Collectively, these results
101 highlight the potential of repurposing GA as a future therapy for patients with heart diseases.

102

103 **RESULTS**

104 **Transient treatment with GA results in improved cardiac function after acute MI**

105 Searching for drug candidates that could be repurposed to treat heart diseases, we
106 postulated that the beneficial immunomodulatory effects of GA could be harnessed to promote
107 myocardial repair. To test this hypothesis, we subjected adult mice to acute MI²⁴ and divided into
108 two groups, receiving daily intraperitoneal (i.p) injections of either GA or solvent as a control for
109 14 days, starting from the day of surgery (Fig. 1A). While transthoracic echocardiography
110 confirmed the presence of a significant injury in both groups 2 days post-injury (dpi), at 35 dpi, a
111 significant improvement in systolic function was apparent only in the GA-treated group, as
112 displayed by both ejection fraction (EF) and fractional shortening (FS) (Fig. 1B,C). Quantification
113 of the scar area in histological sections showed a significant reduction in infarct size following GA
114 treatment (Fig. 1D,E). In addition, stratification of scar area according to size revealed that large

115 scars, encompassing more than 30% of LV volume, were present only in the control group. GA
116 treatment yielded similar results also when calculating ischemic area-at-risk and infarct zone at 4
117 dpi (Fig. 1F,G), excluding the possibility of surgical inconsistencies in the findings and ensuring
118 the quality control of the procedure.

119 Subsequently, we tested whether the therapeutic window for GA administration might be
120 extended, which is relevant for the treatment of late-arrival MI patients²⁵. To that end, mice were
121 subjected to MI and treatment was postponed for 24- or 48-hours post-MI. Results showed that
122 delayed administration of GA improved systolic function to a similar extent as compared to
123 immediate treatment (Fig. 1H). This suggests a wide temporal window for GA administration,
124 relevant for late arrival patients.

125

126 **GA treatment attenuates acute inflammatory response and promotes a pro-reparative** 127 **immune phenotype after acute MI**

128 Following acute MI, the ischemic myocardium activates an intense inflammatory response,
129 mostly of the innate immune system, followed by infiltration of neutrophils and bone marrow-
130 derived monocytes. The early dominance of innate immunity is then replaced by an adaptive
131 immune response²⁶. Based on the known immunomodulatory effects of GA in various models of
132 organ injury^{23,27,28}, we postulated that it would inhibit the acute inflammatory response following
133 MI and promote a pro-reparative immune phenotype. To gain deeper insights on the effects of GA
134 on the inflammatory response following acute MI, we performed single-cell expression profiling
135 on CD45⁺-enriched cardiac cells at 1 and 4 dpi, using the 10x Genomics Chromium platform.
136 Adult mice were subjected to acute MI and treated daily with either GA or control until their
137 sacrifice (Fig. 2A). Echocardiography performed at 3 dpi demonstrated a significant beneficial

138 effect in the GA-treated group on %EF already at this early timepoint, indicating a potential
139 protective effect of GA on the ischemic myocardium (Fig. 2B). Transcriptional profiles of 49,369
140 cells were captured after quality control filtering. Distinct cell populations, represented by a total
141 of 19 clusters, were visualized in uniform manifold approximation and projection (UMAP)
142 reduced dimensionality plots (Fig. 2C and Fig. S1A). Cluster annotation was performed using
143 canonical markers for each cell type (Fig. 2C and Methods).

144 Neutrophils are the first immune cells to infiltrate the myocardium in response to injury,
145 peak at day 1 and quickly undergo apoptosis thereafter²⁹. As expected, neutrophils were the
146 predominant immune cells detected at 1 dpi (~26.3% of total cells), and by day 4 their numbers
147 substantially decreased to 5.6% of total cells (Fig. 2D), validating the injury. The
148 monocytic/macrophage population demonstrated opposite kinetics, comprising 26% of total cells
149 in 1 dpi, and increasing to 48.5% by day 4. Of note, at 1 dpi the majority of *Cd68*⁺ monocytes
150 were *Lyve1*⁺*Timd4*⁺ resident cardiac macrophages, which were further increased at 4 dpi due to
151 the accumulation of *Lyve1*⁻*Timd4*⁺ macrophages (Fig. 2D). Another validation for the injury can
152 be shown by the activation of *Coll1a1*⁺*Postn*⁺ myofibroblasts that increased by 12-fold at 4 dpi
153 (Fig. 2D).

154 The average abundance of T- and B-cells was largely constant (~4% each, not shown),
155 consistent with the known slower kinetic of adaptive immunity³⁰. Excessive neutrophil activation
156 has been associated with increased infarct sizes due to the increased tissue damage³¹ and with
157 occurrence of fatal ventricular fibrillation³². We identified a distinct neutrophil cluster based on
158 canonical markers (Fig. 2E). Differential gene analysis comparing the GA and Control groups at
159 1 dpi demonstrated 726 differentially expressed genes (DEG) as well as down-regulation in
160 neutrophil activation markers such as *S100a8* and *S100a9* in the GA group (Fig. 2F-G). These

161 genes bind to Toll-like receptors and activate inflammasome-dependent pathways, thereby
162 intensifying inflammatory activation, resulting in increased damage³³. Ingenuity pathway analysis
163 (IPA) of DEG demonstrated in the GA treated mice down regulation in pathways related to
164 *Inflammatory response*, and upregulation in pathways related to *Free radical scavenging*,
165 *Senescence*, *STAT3* and *Autophagy*, associated with neutrophil silencing and clearance from the
166 tissue³⁴ (Fig. 2H). To substantiate these findings, we analyzed neutrophil myocardial infiltration
167 at 1 dpi using FACS, which demonstrated that GA administration had resulted in a significant
168 reduction in their numbers (Fig. 2I and Fig. S1B). The attenuation of the inflammatory response
169 at 1 dpi was further demonstrated by the significant reduction observed in serum levels of pro-
170 inflammatory cytokines induced by GA treatment (Fig. 2J).

171 Th2 cells and Tregs play an essential role in the resolution phase of tissue injury and in
172 promoting repair processes in various tissues, including the heart³⁵. The immunomodulation
173 activity of GA in patients with MS includes the stimulation of Th2-like responses¹³, with
174 concomitant elevation of Tregs^{16,36}. We detected a distinct cluster of *Cd3e+Cd3d+* T cells (Fig.
175 2K). IPA performed on the DEG between GA and control at 4 dpi revealed down-regulation in
176 numerous pathways related to immune activation and upregulation in a pathway related to Treg
177 cells (Fig. 2L). Immunostaining and flow cytometry demonstrated elevation in Tregs levels in
178 GA-treated hearts (Fig. 2M and Fig. S1C), indicating that in addition to the immediate effect of
179 GA on the pro-inflammatory response, it can also modulate the immune response in the injured
180 heart towards reparative inflammation.

181 In the regenerative murine neonatal heart, tissue-resident macrophages expand and
182 dominate the injured area, resulting in reduced inflammation, enhanced angiogenesis, and CM
183 proliferation⁸. However, in adult mice, this resident macrophage population is replaced, or

184 outnumbered, by monocyte-derived macrophages that are prominently pro-inflammatory⁸. Thus,
185 coordinated temporal activation of distinct macrophage populations might be essential for cardiac
186 healing. We detected a cluster of *Timd4*⁺ resident cardiac macrophages that expanded in size by
187 4 dpi (Fig. 2K lower panel). IPA performed on the DEG between GA and control at 4 dpi revealed
188 metabolic signatures favoring *Glycolysis*, *Gluconeogenesis* and *cellular growth and proliferation*.
189 In addition, we noted a down regulation in pathways related to *Il-6 Signaling* and *natural killer*
190 *cell signaling*, which could reflect a reparative phenotype induced by the *Timd4*⁺ resident
191 macrophages (Fig. 2L). To corroborate this, we followed the dynamics of cardiac macrophage
192 profiles at 4 dpi using FACS and detected a significant increase in the levels of TIMD4⁺ resident
193 cardiac macrophages that limit adverse remodeling after MI³⁷ in the hearts of GA-treated mice
194 (Fig. 2M).

195 Taken together, our data support an early anti-inflammatory effect induced by GA
196 treatment. This is demonstrated by transcriptomic changes indicating reduced neutrophil
197 activation, reduced myocardial infiltration of neutrophils, as well as by reduction in serum pro-
198 inflammatory cytokines. Additionally, we provide evidence that GA induces a pro-reparative
199 immune phenotype, reflected by transcriptomic changes seen at single cell level of T cells and
200 cardiac resident macrophages, which are further supported by FACS and immunofluorescence
201 analyses.

202

203 **Single cell profiling suggests multiple effects on endothelial and fibroblasts induced by GA** 204 **treatment following MI**

205 The single cell suspensions for the scRNA-seq experiment were enriched for CD45⁺ to
206 mainly focus on the myocardial immune response following GA treatment. As expected, the

207 samples also contained 11708 non-immune cells (mainly endothelial cells (EC) and cardiac
208 fibroblasts (CF)). To gain better insight on these populations, we re-clustered them and generated
209 an unbiased targeted UMAP for each population (Fig. S2A and Fig. 3A-C). The ECs consisted of
210 6 different clusters: lymphatic, venous, arterial, and 3 distinct capillary endothelial clusters (Fig.
211 S2A). IPA performed on the DEG at 1 dpi of the general endothelial cluster demonstrated
212 enrichment in pathways related to *Vasculogenesis*, *cell survival* and *cell movement* and down
213 regulation in pathways related to *cell death of endothelial cells* in the GA group compared to
214 control. This reflects a possible protective and proangiogenic effect induced as early as 1 day
215 following GA treatment (Fig. S2B). Capillary sub-clustering consisted of Capillary-1 and
216 Capillary-2 were detected at 1 dpi whereas Capillary-3 emerged only at 4 dpi (Fig. S2C). A
217 Frequency plot revealed that the GA-treated group was enriched for Capillary-1, while Capillary-
218 2 was more prevalent in the control group (Fig. S2D). Further pathway analysis demonstrated that
219 Capillary-1 cluster is enriched with pathways related to *blood vessel morphogenesis* and various
220 *angiogenesis* pathways, whereas the Capillary-2 cluster was enriched with inflammatory
221 pathways, including pathways related to *interleukin-1 beta production* and *leukocyte cell-cell*
222 *adhesion*, further supporting an angiogenic effect of GA (Fig. 2SE-F).

223 The CF UMAP consisted of a distinct cluster of myofibroblasts and quiescent fibroblasts,
224 2 clusters of pericytes, and a distinct monocytic cluster (Fig. S3A). The monocytic cluster that was
225 found in the targeted UMAP of both fibroblasts and endothelial cells expressed both monocytic
226 gene markers as well as endothelial- or fibroblasts- markers, probably reflecting stromal cell
227 phagocytosis by recruited monocytes/macrophages (Figs. S2A and S3B). As expected, these
228 monocytes were absent at 1 dpi and appeared only at 4 dpi, reflecting the known kinetics of
229 monocytic recruitment to the tissue. Pathway analysis of DEG revealed an intense activation of

230 fibroblasts at 1 dpi in the GA- treated group compared to control, with enrichment of pathways
231 related to *Wound Healing Signaling* (Fig. S3D, left). The analysis at 4 dpi demonstrated an
232 opposite expression pattern, characterized by profound silencing of fibroblast activation, as
233 evidenced by down regulation in pathways related to *Wound Healing*, and various pathways of
234 *Fibrosis* (Fig. S3D, right). These data suggest that GA might induce a biphasic fibroblast activation
235 response, characterized by an early acute activation, required for the immediate response, followed
236 by a profound inactivation, that could reduce the deposition of collagen and the progression of
237 fibrosis.

238 Overall, these data suggest that GA affects the transcriptome of cardiac ECs and
239 fibroblasts. In fibroblasts it induces a biphasic activation and silencing pattern, and in ECs it
240 promotes the protection and angiogenic responses.

241
242 **Extracellular vesicles isolated from GA-treated hearts carry a pro-reparative cargo and can**
243 **recapitulate the beneficial effects of GA after acute MI**

244 Next, we explored the impact of GA therapy on the proteomic landscape at 4 dpi. Here too,
245 echocardiography of injured mice performed at 3 dpi indicated that the decline in systolic
246 parameters was mitigated in GA-treated mice, indicating a potential protective effect of GA on the
247 ischemic myocardium (Fig. 3A,B). Principle component analysis (PCA) performed at 4 dpi
248 revealed three distinct clusters according to the treatment (uninjured, MI-control, MI-GA) (Fig.
249 3C). A total of 93 DE proteins were detected in the control group and 178 in the GA group (Fig.
250 3D). Pathway analysis of the DE proteins showed enrichment in pathways of innate immunity,
251 leukocyte chemotaxis, T cell proliferation, and cell motility and migration in the GA treated hearts,
252 all consistent with substantial modulation of the immune response (Fig. 3E). In addition, we noted

253 a significant enrichment in proteins related to extracellular vesicles (EVs) (Fig. 3E). EVs are
254 membrane-containing organelles, of 30-120 nm in diameter, which are secreted through
255 exocytosis, carrying distinct cargo capable of exerting a myriad of effects, including repair^{38,39}.
256 Additionally, the protective effect of endothelial cell-derived EVs was recently shown in a human
257 heart-on-chip model⁴⁰, suggesting that GA could act by paracrine signaling mediated by EVs.

258 We therefore examined whether cardiac EVs derived from GA-treated animals can
259 recapitulate the beneficial effects of GA on cardiac function after injury. For that, we isolated
260 cardiac EVs from mice subjected to acute MI (Fig. S4A-D). Based on the proteomic analysis
261 results, animals were treated for 3 days with either GA or control and on day 4 EVs were isolated
262 from the LV and were administered immediately after LAD ligation to a second cohort of mice
263 (Fig. 3F). Consistent with the proteomic data, a significant reduction in %EF values was apparent
264 in animals that received a single intramyocardial injection of control-derived EVs or PBS (Fig.
265 3G,H). Notably, the reduction in systolic function was blunted by administration of EVs derived
266 from GA-treated mice (Fig. 3G,H). In addition to functional cardiac improvement, histological
267 analysis revealed a significant reduction in infarct size following GA-derived EV treatment,
268 compared to control-treated hearts (Fig. 3I,J). As myocardial perfusion is a major determinant of
269 cardiomyocyte death following acute ischemia, we assessed arterial density in the infarct zone. A
270 significant increase in α SMA⁺ blood vessels and in CD31⁺ cells was observed in mice that were
271 treated with GA-derived EVs compared to control EVs at 4dpi (Fig 3I-K, Fig S5), suggesting that
272 GA-derived EVs exert a protective effect on myocardial coronary arteries. The strong α SMA⁺
273 staining observed inside the scar region, mainly in control hearts, reflects activated myofibroblasts.
274 Taken together, our results suggest a protective effect of GA-derived EVs on CMs and coronary
275 vasculature.

276 To analyze the differential protein content of cardiac EVs derived from GA- or control-
277 treated hearts, we performed proteomic analysis of these vesicles. PCA revealed three distinct
278 clusters: GA-derived, control-derived EVs, or EVs from uninjured hearts (Fig. 3L), indicating GA-
279 dependent differences. Overall, 455 proteins were found to be significantly changed in the GA-
280 derived EVs (Fig. 3M). GA-derived EVs exhibited significant enrichment in numerous gene
281 ontology (GO) terms, such as negative regulation of apoptotic processes, cardiac contractility,
282 respiratory chain, mitochondrion, and ribosome (Fig. 3N). A targeted heatmap based on the
283 individual proteins that comprise these pathways further highlighted distinct proteins in GA-
284 derived EVs that might be involved in improving systolic function or exerting CM protective
285 effects, such as Birc6, SERCA2 and phospholamban (Fig. 3O). Together, these results reveal a
286 distinct myocardial proteomic signature induced by GA therapy, which is associated with pro-
287 reparative EV secretion that can recapitulate GA's reparative effects.

288

289 **GA promotes cardiac tissue protection, angiogenesis, and reduced cardiac fibroblast** 290 **proliferation**

291 An immediate detrimental effect of tissue ischemia is loss of CMs due to necrotic and
292 apoptotic cell death. Apoptotic cell death starts already 2h after injury and can last for weeks⁴¹.
293 Based on the proteomic data demonstrating enrichment in anti-apoptotic pathways (Fig. 3N,O),
294 and the consistent preserved systolic functions already at 3 dpi (Fig. 2B and Fig. 3A,B), we
295 hypothesized that reduced levels of apoptosis would be detected after GA treatment. Indeed,
296 TUNEL assay at 24h and 96h post-injury revealed less apoptotic CMs in the ischemic border zone
297 of GA-treated hearts (Fig. 4A-E). Additionally, we observed an increase in the expression of the
298 anti-apoptotic protein, Bcl-XL, in the border zone and injured area of GA-treated mice (Fig.

299 S6A,B), indicating an immediate protective effect of GA on the injured heart. These findings were
300 further supported using a 3D *ex vivo* organ culture (EVOC) model of adult mouse hearts (Fig.
301 S6D-H), where we exposed cardiac slices to H₂O₂, a reactive oxygen species (ROS) that causes
302 cellular damage, thereby mimicking the pathophysiology of reperfusion injury. TUNEL assay and
303 IF of γ H2AX revealed reduced levels of DNA double-strand breaks in GA treated samples (Fig.
304 S6D-H), suggesting a protective effect of GA also in the *ex vivo* model.

305 While early cardiac fibroblast (CF) activation is vital for replacing the scaffold of necrotic
306 tissue, late and excessive CF proliferation can impair proper heart function due to stiffening of the
307 myocardium⁴². Staining heart sections with vimentin and Ki67 revealed intensive migration of
308 CFs to the injured site in both GA-treated and control hearts 24h after injury (Fig. 4F). Yet, at 96h
309 post-MI, GA suppressed CF proliferation within the scar region, relative to control (Fig. 4F,G).

310 Following the observed protective effects of GA and the induction of reparative
311 inflammation, we next addressed its capacity to induce repair processes. A crucial aspect of the
312 repair process after MI is the restoration of blood supply to the ischemic myocardium. Adequate
313 angiogenesis can improve myocardial perfusion as well as crosstalk between CMs and endothelial
314 cells (ECs), which improves CM function through angiocrine signals⁴³. Quantification of CD31⁺
315 cells revealed enhanced capillary formation within the scar area of GA-treated hearts (Fig. 4H,I),
316 which was accompanied by ~5-fold increase of blood vessels (Fig. 4E,F), at 14 dpi (Fig. 4J,K).
317 This suggests that in addition to the protective effect of GA, which results in enhanced survival of
318 blood vessels at the injured site, it can induce endothelial cell proliferation.

319 Taken together, these results demonstrate that GA treatment exerts pleiotropic beneficial
320 effects that include CM protection, modulation of fibroblast activation, induction of a reparative

321 inflammatory response and enriched vascularization, leading to improved cardiac repair and
322 function following MI (Fig. S7).

323

324 **GA confers protection of cultured cardiomyocytes from stress-induced cell death in a cell**
325 **non-autonomous manner**

326 While the neuroprotective effects of GA are mainly attributed to its immunomodulatory
327 properties, *in vitro* data suggest that it has a direct protective effect on cultured neurons in the
328 absence of immune cells⁴⁴. To determine whether GA exerts a protective effect on CMs
329 independent of immune cells, we used an *in vitro* cardiac culture model. Flow cytometry verified
330 that the cultures contained negligible amounts of immune cells (Fig. S8A). Cardiac cultures
331 derived from 3 days old (P3) mice were treated with the pro-apoptotic agent staurosporine (STS)
332 or with H₂O₂. Cell death and apoptosis were analyzed using DAPI exclusion or TUNEL assays,
333 respectively, with or without GA. CMs that were treated with STS for 18 hours in the presence of
334 GA displayed reduced apoptosis and cell death (Fig. 5A and Fig. S8B). Control CMs under STS-
335 induced stress lost their typical morphology and intact sarcomeric structure, whereas most GA-
336 treated CMs maintained a typical appearance (Fig. 5A). Additionally, 48h after the addition of
337 STS, more CMs survived in GA-treated cultures compared to control (Fig. 5B). Similarly,
338 exposure of cardiac cultures to H₂O₂ revealed a significant protection of CMs in GA-treated
339 cultures compared to control (Fig. 5C).

340 Cultured cardiac cells derived from P3 mice contain various cell types, including CMs,
341 CFs and ECs. To detect the localization of GA in these cells, we administered GA conjugated to
342 FITC (FITC-GA) and then labeled specific cell types using immunofluorescence staining. FITC-
343 GA maintained its activity and induced a similar protective effect *in vitro* as unlabeled GA (Fig.

344 S8C). Accumulation of FITC-GA started rapidly after its administration (Fig. 5D). As previously
345 described, GA was localized in the cytoplasm of labeled cells⁴⁴, most of them positive for CD31
346 or vimentin (Fig. 5D). Interestingly, while CMs were not labeled even after prolonged incubation
347 of 48h, they localized around the FITC-GA-labeled cell clusters. Labeling was also quite negligible
348 in myofibroblasts, as shown by lack of FITC-GA in cells expressing SMA (Fig. 5D). The EVOC
349 model of adult hearts showed a similar pattern of FITC-GA labeled cells, which accumulated
350 mainly in interstitial cells and not in CMs (Fig. 5E), further supporting a paracrine effect exerted
351 by neighboring stromal cells on the CMs.

352 The *in vivo* data indicating involvement of GA-derived EVs in mediating GA's therapeutic
353 effect, together with the absence of FITC-GA from CMs, strongly suggest a cell non-autonomous
354 signaling as the mechanism of action whereby GA induces CM protection. To test this hypothesis,
355 we used conditioned media from CM-depleted cardiac cultures (Fig. S8D), that were treated with
356 either GA or control. After washing the residual GA, conditioned media was collected and used
357 for ROS assay, i.e., challenge with H₂O₂ (Fig. S8E). GA-conditioned media from CM-depleted
358 cultures reduced CM mortality following ROS exposure compared to control conditioned media
359 (Fig. S8F), further verifying that GA acts in a paracrine manner via fibroblasts and ECs.

360

361 **GA induces spatial organization of cardiomyocytes and endothelial cells, while inhibits** 362 **mouse and human CF proliferation**

363 Next, we examined the effect of GA treatment on the growth of distinct cardiac cell
364 populations *in vitro*. While we detected no effect on CM proliferation (not shown), GA treatment
365 promoted the accumulation of ECs (Fig. 5F,G), further corroborating the findings obtained from
366 the scRNA-seq analysis and the enhanced vascularization observed *in vivo*. To determine the long-

367 term effects of GA on cardiac cultures, we followed the fate of CMs and ECs for up to 14 days of
368 culture in the presence of GA. Immunostaining revealed a striking difference in the spatial
369 organization of CMs. While in the absence of GA, CMs were randomly dispersed as usually
370 observed in cardiac cultures (Fig. 5H, left panels), in GA-treated cultures, CMs rearranged in a
371 process resembling tube formation. Co-staining revealed that GA induced tight association of
372 CD31+ ECs with CMs (Fig. 5H, right panels). This spatial organization of ECs and CMs was
373 previously shown to promote improved survival and beating of CMs⁴⁵, as well as cardiac
374 remodeling and regeneration⁴³. RT-qPCR analysis verified the enrichment of both CM and EC
375 populations in prolonged GA-treated cultures (Fig. 5I). Thus, GA triggers spatial association
376 between CMs and ECs, leading to their enhanced survival. In accordance with the *in vivo* data, GA
377 inhibited the proliferation of cultured CFs derived from either mouse hearts (Fig. S8G,H) or human
378 cardiac biopsies (Fig. S8I).

379 Taken together, our *in vitro* data correlate with the observed effects of GA *in vivo* and *ex*
380 *vivo*, showing that in addition to its pro-reparative immunomodulatory activity, GA directly
381 promotes beneficial effects *in vitro* by improving CM survival, enhancing angiogenesis, and
382 reducing CF proliferation.

383

384 **Transient treatment with GA improves heart function in a rat model of heart failure**

385 Despite dramatic improvements in interventional cardiology that, over the past three
386 decades, have reduced the mortality associated with acute MI, the prevalence of HF is on the rise.
387 HF is associated with chronic inflammation. Our results in the acute MI mouse model prompted
388 us to determine whether treatment with GA could have beneficial effects on the failing heart. For
389 that, we induced MI in a rat model of permanent LAD ligation, allowing post-MI ventricular

390 remodeling to progress for 28 days before starting treatment with GA or a control solvent. The
391 severity of the injury was determined by monitoring EF values three weeks post-MI, after which
392 the rats were divided into two experimental groups with similar measurements (Fig. 6A). The
393 development of HF was validated by detection of ventricular remodeling by echocardiography
394 (based on LV internal diameter in diastole) and upregulation of *nppb* in cardiac tissue (Fig. 6B,C).
395 To prime GA-induced immunomodulation, rats were first treated with i.p GA injections daily for
396 7 days, followed by three weekly injections for 2 months. Echocardiography measurements were
397 performed at the end of treatment (93 days) and 1 month later (120 days). After 2 months of
398 treatment, the GA group displayed a significant improvement in cardiac function, as shown by a
399 mean increase of ~30% in EF and ~59% in FS parameters, compared to the control group (Fig.
400 6D-F). Remarkably, 1 month after discontinuation of GA therapy, further improvement was
401 observed in EF (48% increase), and the improvement in FS values was maintained (45% increase),
402 in the GA treated group (Fig. 6E,F, and <https://youtu.be/xKbnnBUaKF4>, <https://youtu.be/ZlulgET60e4>). Examination of individual rats revealed that most of GA-treated animals had improved
403 EF and FS values, whereas control rats displayed worsened parameters (Fig. 6G,H). In addition to
404 improvement in systolic function, GA-treated rats demonstrated reduced adverse remodeling of
405 the LV, reflected by the reduced LV dimensions (Fig. 6I,J). While the control group demonstrated
406 a persistent increase in interstitial fibrosis from 21 to 120 dpi, GA significantly inhibited this
407 increased collagen deposition as shown by Masson Trichrome staining (Fig. 6K). These results
408 suggest that a short 2-month GA treatment regimen results in persistent beneficial remodeling
409 effects on the LV, reduced myocardial fibrosis and enhanced LV contractility.
410

411

412 **GA treatment blunts the cytokine surge associated with ADHF and reduces serum levels of**
413 **NT-proBNP in a small phase 2a clinical study**

414 The clinical syndrome of HF involves a vicious cycle where myocardial and systemic
415 inflammatory processes cause further ventricular and hemodynamic deterioration⁴⁶. Based on the
416 effects we observed on myocardial injury in rodents and its excellent safety profile in humans, we
417 postulated that GA could be repurposed to treat myocardial injury by preventing cardiac
418 remodeling. To test this, we conducted a small proof-of-concept, phase 2a, open-label,
419 randomized-controlled trial to assess the effects of GA treatment on the inflammatory profile of
420 patients admitted to the hospital due to ADHF. Briefly, patients were eligible for participating if
421 they had a confirmed diagnosis of HF with reduced systolic function ($EF \leq 40\%$), were clinically
422 stable for the preceding month and on maximally tolerated guideline-directed medical therapy
423 (GDMT) for at least 3 months. Major exclusion criteria included acute coronary syndrome, current
424 infection, active treatment with anti-inflammatory agents or low compliance to medical therapy.
425 Patients were randomly assigned in a 1:1 ratio, to receive GDMT alone or GDMT in addition to
426 daily subcutaneous injections of GA (20mg daily), for 14 days. Baseline echocardiography was
427 available for all patients at the time of enrollment. Patients were followed closely during
428 hospitalization and up to 3 months thereafter. Blood samples were collected at days 0, 2, and 14
429 (Fig. 7A). The primary outcome was a change in serum inflammatory profile from baseline to days
430 2 and 14. Secondary outcomes included serum levels of cardiac biomarkers (high-sensitivity
431 troponin and NT-proBNP), creatine kinase, and repeated hospitalizations due to ADHF within 3
432 months of follow-up. As this was the first clinical trial testing GA effects on patients with HF, we
433 evaluated safety parameters, including adverse reactions, kidney function (using serum creatinine
434 levels) and liver function (by monitoring liver enzymes).

435 Between June 2021 and June 2022, 67 patients admitted to the participating medical center
436 with ADHF were screened. Of them, 14 patients who met the inclusion criteria were recruited.
437 Eight patients were randomized to the GA plus GDMT group, and 6 to the GDMT alone group
438 (Fig. 7B). Two patients (one from each group) that required in-patient cardiac catheterization were
439 excluded from the analysis of primary outcome. There were no significant differences in baseline
440 characteristics between the two groups (Fig. S9A and Fig. 7C). GA therapy resulted in a significant
441 blunting of the cytokine surge associated with ADHF starting early at day 2 and maintained at day
442 14 following hospital admission (Fig. 7D). While the levels of serum cytokines in the standard
443 care group increased from baseline measurements to day 14, GA-treated patients had significantly
444 lower cytokine levels both at days 2 and 14. A post hoc analysis of individual cytokines performed
445 after exclusion of 2 patients with abnormally high cytokine levels at day 14 (1 from each group),
446 demonstrated a consistent trend of GA-mediated reduction throughout the various types of
447 cytokines analyzed (Fig. 7E).

448 NT-proBNP is a natriuretic peptide that is mainly secreted by ventricular CMs in response
449 to wall stretch associated with volume overload and elevated filling pressures, which are the *sine*
450 *qua non* of ADHF. This cardiac biomarker serves for diagnostic as well prognostic purposes with
451 excellent correlation with HF severity and response to therapy⁴⁷. Therefore, we examined changes
452 in NT-proBNP circulatory levels in these ADHF patients with and without GA therapy. GA
453 treatment resulted in a significant reduction in serum levels of NT-proBNP at days 2 (45%) and
454 14 (57%) after normalization to baseline levels (Fig. 7F, left), whereas in the control group, NT-
455 proBNP levels increased by 10% and 31%, respectively (Fig. 7F, $p=0.03$ for both time points).
456 When comparing the change in NT-proBNP values between baseline and day 14, a clear decrease
457 in NT-proBNP levels was observed in the GA-treated group (-59%), while NT-proBNP levels

458 were increased in the control group (+112%) (Fig. 7F, right and Fig. S9B). Scatter plot of cytokines
459 and NT-proBNP levels revealed two distinct clusters of treated versus untreated patients (Fig. 7G).
460 As an exploratory clinical outcome, we recorded the rate of re-hospitalizations due to HF during
461 the first 3 months from the index hospitalization. Three patients (25%) were re-admitted to the
462 hospital due to HF exacerbation (1/7 in the GA group and 2/5 in the control group) (Fig. S9C),
463 thus the study was underpowered to show statistically significant differences. We did not detect
464 significant differences in plasma levels of myocardial injury markers (high-sensitivity troponin or
465 creatine kinase, data not shown). There were no mortality events observed during the follow-up
466 period. No adverse reactions were reported throughout the course of the study, and no changes in
467 complete blood counts and kidney or liver function were noted.

468 Lastly, we performed proteomic analysis of EV-enriched sera from all patients at baseline,
469 day 2 and day 14 (Fig. S10A-C). While baseline PCA did not show separate clustering of the
470 standard care and GA groups, a separate cluster of GA-treated patients was evident at days 2 and
471 14 (Fig. S10D). An unsupervised heat map generated from differentially expressed (DE) proteins
472 at day 2 revealed a clear proteomic signature of the GA-treated patients (Fig. S10E). The main DE
473 proteins were matricellular proteins (Tenascin, SPARCL1) that are associated with extracellular
474 matrix remodeling, as well as proteins related to tissue stress (PRDX2 and KDM4C) (Fig. S10F).
475 These data, obtained by an unbiased, high-throughput assay, further demonstrate the broad impact
476 of GA treatment.

477 478 **DISCUSSION**

479 We show here for the first time that the immunomodulator drug GA can induce reparative
480 processes in rodent models of acute MI and ischemic HF and to significantly suppress the cytokine
481 surge associated with ADHF in hospitalized patients. Our study is thus unique in combining basic

482 preclinical research along with a small clinical trial suggesting GA as a potential new therapy for
483 heart diseases. This study also stresses the potential of drug repurposing strategy, which markedly
484 accelerates the process of drug development.

485 Acute MI triggers intense activation of the immune system that is required for the repair
486 process, promoting clearance of necrotic debris, and initiating a pro-regenerative tissue response
487 ⁴⁸. The various stages and components of immune cell activation must be strictly regulated to
488 prevent secondary myocardial damage, adverse remodeling, and the development of HF. As GA
489 is primarily known for its immune modulating effects, we initially performed a thorough
490 characterization of the cardiac inflammatory response following GA treatment, revealing multiple
491 beneficial effects on neutrophils, macrophages, and T cells. These effects encompassed extensive
492 changes in gene expression profiles, evaluated at the single cell level, as well as in immune cell
493 tissue infiltration and cytokine secretion. It has been previously shown that an acute immune
494 response can account for the beneficial effects attributed to cardiac stem cell therapy, specifically
495 by modulating regional macrophages subtypes ⁴⁹. The combined effects of reduced neutrophil
496 activation together with up regulation in TIMD4⁺ resident cardiac macrophages and Tregs is
497 expected to culminate in less collateral myocardial damage and a pro-reparative *milieu*. Indeed,
498 we detected reduced CM apoptosis as early as 24h following injury, coinciding with the peak of
499 neutrophil infiltration. In addition, we observed reduced CF activation, coronary vasculature
500 protection and increased angiogenesis. We subsequently showed the therapeutic effects of GA in
501 a rat model of ischemic HF, which further substantiated the broad capability of GA to prevent
502 deterioration of the injured heart and enhance the reparative process.

503 Interestingly, apart from the known immune-modulating activity of GA, we provide
504 evidence for pleiotropic effects *in vitro* in cardiac cultures lacking immune cells, which include

505 CM protection and angiogenesis. The specific uptake of FITC-conjugated GA by CFs and ECs but
506 not CMs, as well as the protective paracrine effects of GA-treated conditioned medium collected
507 from CM-depleted cardiac cultures, suggest that these effects are, at least partly, mediated by
508 secreted factors. The *in vivo* results of GA-derived cardiac EVs, which are enriched with proteins
509 that promote anti-apoptotic effects and enzymes that participate in oxidative phosphorylation,
510 support the paracrine effects observed *in vitro*, and suggest that these vesicles could also improve
511 CM metabolism. Taken together, we propose that GA exerts a bidirectional effect; on one hand, it
512 promotes CM protection that results in reduced immune activation, and, on the other hand, it
513 attenuates the acute immune response, thereby minimizing secondary tissue damage (Fig. S7).

514 Inflammation contributes to the pathogenesis and progression of HF, and specifically of
515 acute exacerbations⁴⁶. The magnitude of the inflammatory response in ADHF patients was found
516 to be in correlation with the serum levels of NT-proBNP and is associated with a considerable risk
517 of death within the subsequent 12 months from hospitalization^{50,51}. Therefore, we decided to test
518 the efficacy of GA in inhibiting the cytokine surge associated with ADHF, thus potentially
519 improving cardiovascular outcomes in this patient subset. It is important to note that the objective
520 of this clinical study was to provide preliminary human data on the safety and potential efficacy
521 of GA therapy to reduce the cytokine surge, neurohormonal activation and myocardial
522 hemodynamic stress among patients with ADHF. The efficacy and high safety profile of GA have
523 been documented in many clinical trials in large cohorts of patients treated for extended time
524 periods⁵²⁻⁵⁴. However, the drug has not been previously tested in patients with a heart disease, and
525 there is a previous theoretical assumption that GA may be responsible for modulating the risk of
526 coronary artery disease⁵⁵. Importantly, we did not observe any adverse effects in the treated
527 patients, though larger patient cohorts will be necessary to confirm the safety of GA for this

528 indication. Consistent with the results obtained in our preclinical models, we noted a profound
529 general reduction in the levels of both pro- and anti- inflammatory cytokines after a short-term
530 treatment with GA. The general silencing of both pro- and anti- inflammatory mediators promoted
531 by GA is consistent with previous reports, demonstrating worse outcomes in patients in whom the
532 general cytokine surge was not decayed^{50,51}. In addition, we detected significant reductions in the
533 levels of NT-proBNP in the GA-treated group. As hospitalized patients with ADHF whose NT-
534 proBNP levels remain high despite treatment are at substantially increased risk of death⁵⁶, GA's
535 effects on natriuretic peptides might be a surrogate for improved clinical outcomes.

536 Taken together, our findings indicate that GA may have an advantage in promoting
537 myocardial repair over other immune-modulating agents tested thus far, as it not only targets
538 several different aspects of the immune response and drives a pro-reparative immune phenotype,
539 but also exerts multiple pleiotropic effects on the myocardial cellular milieu⁵⁷. These additive
540 effects might be especially appealing for the treatment of HF, a disease with a considerable
541 inflammatory component. Although exploratory in nature, the significant effects of GA detected
542 in the small phase 2a clinical trial, and its safety use for ADHF patients, suggest a novel therapeutic
543 potential of GA that should be assessed in larger clinical trials.

544

545

546 **MATERIALS AND METHODS**

547 **Study design - animal models** *Sample size:* For the *in vivo* cardiac injury models, we used a
548 sample size that has previously been shown to yield significant differences in cardiac parameters,
549 such as EF, FS, and scar size. Thus, 5-10 animals were used in each experimental group, depending
550 on the purpose of the experiment and on variation in the observed severity of injuries in individual
551 animals. *Data inclusion/ exclusion criteria:* For the HF experiments, animals that did not show

552 sufficient injury (EF>45%) or had too severe injury (EF <30%), as measured before the beginning
553 of treatment, were not included in the final analysis. *Replicates*: The exact replicate number for
554 each experiment is provided in the figure legends. *Research objectives*: The research was designed
555 to examine the effects of GA in MI and HF rodent models and its mechanism of action. *Research*
556 *subjects or units of investigation*: We used ICR female mice and Sprague Dawley rats as models
557 of cardiac ischemic injury (acute and chronic), as well as primary mouse cardiac cell cultures.
558 *Randomization*: In the HF experiment, animals were paired according to their EF data at 21 days
559 post-LAD ligation and assigned randomly to either GA or control group. *Blinding*: Animals were
560 assigned numbers and echo and histology outcomes were assessed by a blinded investigator.

561 **Myocardial infarction.** All animal experiments were approved by the Weizmann Institute of
562 Science Institutional Animal Care and Use Committee (IACUC) and were conducted in
563 compliance with the guidelines and regulations regarding animal research.

564 *Mice*: 12-week-old ICR females were sedated with 3% isoflurane (Abbot Laboratories) and then
565 artificially ventilated following tracheal intubation. Experimental myocardial infarction was
566 induced by permanent ligation of the left anterior descending coronary artery as previously
567 described ⁵⁸. Following thoracic wall closure, the mice were injected subcutaneously with
568 buprenorphine (0.066 mg/kg⁻¹) as an analgesic, and warmed until recovery. *Rats*: 8 weeks old
569 Sprague Dawley females were anesthetized with 3% isoflurane, intubated and artificially
570 ventilated. Buprenorphine (0.15 mg/kg SC) was administered before the surgery. Permanent LAD
571 ligation was performed according to the previously published protocol ⁵⁹. The rats were then
572 warmed until recovery.

573 **Echocardiography parameters.** Cardiac function was evaluated by transthoracic
574 echocardiography performed on mice sedated with 2% isoflurane (Abbot Laboratories), using

575 Vevo3100 (VisualSonics). Analysis was performed with the Vevo Lab 3.2.6 software
576 (VisualSonics). Heart rate was continuously monitored using an ECG monitor and remained within
577 350-400 beats/min for the rats and 450-500 beats/min for the mice. EF and FS parameters were
578 measured using the parasternal long axis view (PSLAX), and LVIDd was measured using the M-
579 Mode on the parasternal short axis view (SAX).

580 **EV isolation and verification.** Mice were subjected to permanent LAD ligation and were treated
581 with daily intraperitoneal injections of either GA or mannitol. Animals were sacrificed at 4 dpi,
582 the hearts were perfused with ice-cold PBS, and the LV was isolated and transferred to an
583 Eppendorf tube with 500 μ l of sterile cold PBS. The tissue was minced for 30 sec using fine
584 scissors on ice and then centrifuged twice at 400 g for 15 min. The supernatant was centrifuged a
585 third time at 20500 g for 45 min. Thereafter, the supernatant was transferred to 1.0 mL PC tubes
586 (Levant Technologies, Cat., 45237) and centrifuged at 100,000 g for 1.5 h at 4°C using Sorvall
587 MX120 Ultracentrifuge, rotor S120-AT2, fixed angle, and resuspended in 60 μ l of PBS. EVs were
588 verified according to the position statement of the International Society for Extracellular Vesicles,
589 2018⁶⁰. Briefly, a homogenous solution of nanoparticles measuring 30-120 nm in diameter was
590 confirmed by nanoparticle tracking analysis using NanoSight (Malvern Panalytical).
591 Subsequently, samples were deposited on glow-discharged formvar-coated copper grids for
592 transmission electron microscopy (TEM) and stained with 2% Uranyl Acetate. Images were taken
593 on a Tecnai 12 TEM (Thermo Fisher Scientific), using a TVIPS F416 CMOS camera. Lastly,
594 proteomic analysis showed enrichment of specific EV markers.

595 **EV-mediated reduction in scar area.** Mice were subjected to permanent ligation of LAD and
596 received daily treatment with either 2mg GA, i.p, or an appropriate solvent for 3 days.
597 Subsequently, EVs were isolated from the LV, and used to treat a second cohort of mice using a

598 single intramyocardial (i.m.) injection following LAD ligation. We validated that GA-derived EVs
599 and control-derived EVs were at a similar concentration using NTA (approximately 4×10^9
600 particles/mL) in a volume of 50 μ L.

601 **EV proteomic analysis.** EVs were isolated according to protocol. After ultracentrifugation, pellets
602 were kept at -80°C until analysis. The samples were lysed and digested with trypsin using the S-
603 trap method. The resulting peptides were analyzed using nanoflow liquid chromatography
604 (nanoAcquity) coupled to high resolution, high mass accuracy mass spectrometry (QE HF). Each
605 sample was analyzed separately in a random order in discovery mode. The raw mass spectrometry
606 data were processed with MetaMorpheus version 0.3.20. Data were searched against the mouse
607 UniproKB XML database version 01_2022, with common lab proteins. We applied the spectral
608 recalibration module, G-PTMD module and Search module. Data were normalized and filtered for
609 maximum 1% FDR. Resulting protein table was imported to Perseus. Data were filtered for
610 replication in at least 70% of the replicates in at least one group. Log transformed and missing
611 values were imputed from a low, random distribution. ANOVA was used for statistical evaluation.
612 We used the following threshold for significance: q-value <0.05 , fold-change >2 , and at least 2
613 peptides detected. Gene ontology and pathway analysis was performed using DAVID Analysis
614 Tool, ranked according to $\log_{10}(\text{control-p-value})$.

615 **Cell culture.** Primary cardiac cultures were isolated from P3 mice using a neonatal dissociation
616 kit (Miltenyi Biotec, 130-098-373) and the gentleMACS homogenizer, according to the
617 manufacturer's instructions. Cells were cultured in DMEM/F12 medium (Sigma, D6421) as
618 previously described⁵⁸. The medium was replaced every other day. For most experiments, cells
619 were seeded in 96-well plates at a cell density of 20,000-30,000 cells/well, or at a density of $2-2.5$
620 $\times 10^5/6$ well. Treatment with GA (20-30 $\mu\text{g/ml}$) or control started 4 days after isolation. Cells from

621 FUCCI mice (a generous gift from Dr. Mark Sussman, San Diego State University, CA, USA ⁶¹)
622 were used to follow CM cell cycle.

623 **Clinical trial.** The study was conducted according to the guidelines of the Declaration of Helsinki
624 and approved by the Institutional Review Boards of Hadassah University Medical Center and the
625 Israeli ministry of health (approval number: HMO-093420), and is registered in Israel Ministry of
626 Health clinical trials site ([https://my.health.gov.il/CliniTrials/Pages/MOH_2021-05-](https://my.health.gov.il/CliniTrials/Pages/MOH_2021-05-10_009957.aspx)
627 [10_009957.aspx](https://my.health.gov.il/CliniTrials/Pages/MOH_2021-05-10_009957.aspx)). The study was performed in Hadassah Medical Center, Jerusalem, Israel. Basic
628 laboratory work (complete blood count, serum electrolytes, creatinine, NT-proBNP, hs-troponin,
629 CK and liver enzymes) were performed by the core laboratory of the Hadassah Medical Center as
630 part of the routine clinical patient care. Immune panels, consisting of pro- and anti-inflammatory
631 cytokines, were performed in an independent core research laboratory in Sheba Medical Center,
632 Israel. All laboratory work-up was performed by an independent core laboratory that was blind to
633 patient assignment. All patient samples were anonymous and coded. Cytokine levels were
634 measured using Q-PlexTM Human Cytokine Screen (16-Plex), Q110933HU, and Q-PlexTM Human
635 Chemokine (9-Plex), Q120233HU, Quansys Biosciences, UT, USA.

636 **Statistical analysis.** The results are presented as means \pm SEM and the number of independent
637 biological repeats is indicated for each experiment. Statistical comparisons were carried out by
638 two-tailed Student's *t* test or analysis of variance as appropriate, followed by correction for
639 multiple comparisons using Tukey or Newman-Keuls procedure. Data are presented as mean \pm
640 SEM. Statistical significance was calculated using a two-tailed *t*-test, * $P < 0.05$, ** $P < 0.01$, ***
641 $P < 0.001$.

642

643

644 References

- 645 1 Roger, V. L. Epidemiology of Heart Failure: A Contemporary Perspective. *Circulation*
646 *research* **128**, 1421-1434, doi:10.1161/CIRCRESAHA.121.318172 (2021).
- 647 2 Westman, P. C. *et al.* Inflammation as a Driver of Adverse Left Ventricular Remodeling After
648 Acute Myocardial Infarction. *J Am Coll Cardiol* **67**, 2050-2060,
649 doi:10.1016/j.jacc.2016.01.073 (2016).
- 650 3 Lai, S. L., Marin-Juez, R. & Stainier, D. Y. R. Immune responses in cardiac repair and
651 regeneration: a comparative point of view. *Cell Mol Life Sci* **76**, 1365-1380,
652 doi:10.1007/s00018-018-2995-5 (2019).
- 653 4 Sattler, S., Fairchild, P., Watt, F. M., Rosenthal, N. & Harding, S. E. The adaptive immune
654 response to cardiac injury—the true roadblock to effective regenerative therapies? *NPJ*
655 *Regen Med* **2**, 19, doi:10.1038/s41536-017-0022-3 (2017).
- 656 5 Gelosa, P., Castiglioni, L., Camera, M. & Sironi, L. Drug repurposing in cardiovascular
657 diseases: Opportunity or hopeless dream? *Biochem Pharmacol* **177**, 113894,
658 doi:10.1016/j.bcp.2020.113894 (2020).
- 659 6 Nosengo, N. Can you teach old drugs new tricks? *Nature* **534**, 314-316, doi:10.1038/534314a
660 (2016).
- 661 7 Ziemssen, T., Ashtamker, N., Rubinchick, S., Knappertz, V. & Comi, G. Long-term safety and
662 tolerability of glatiramer acetate 20 mg/ml in the treatment of relapsing forms of multiple
663 sclerosis. *Expert opinion on drug safety* **16**, 247-255 (2017).
- 664 8 Teitelbaum, D., Meshorer, A., Hirshfeld, T., Arnon, R. & Sela, M. Suppression of
665 experimental allergic encephalomyelitis by a synthetic polypeptide. *Eur J Immunol* **1**, 242-
666 248, doi:10.1002/eji.1830010406 (1971).
- 667 9 Aharoni, R. The mechanism of action of glatiramer acetate in multiple sclerosis and beyond.
668 *Autoimmunity reviews* **12**, 543-553 (2013).
- 669 10 Aharoni, R. Immunomodulation neuroprotection and remyelination—the fundamental
670 therapeutic effects of glatiramer acetate: a critical review. *Journal of autoimmunity* **54**, 81-
671 92 (2014).
- 672 11 Fridkis-Hareli, M. *et al.* Direct binding of myelin basic protein and synthetic copolymer 1 to
673 class II major histocompatibility complex molecules on living antigen-presenting cells—
674 specificity and promiscuity. *Proceedings of the National Academy of Sciences* **91**, 4872-
675 4876 (1994).
- 676 12 Aharoni, R., Teitelbaum, D., Arnon, R. & Sela, M. Copolymer 1 acts against the
677 immunodominant epitope 82–100 of myelin basic protein by T cell receptor antagonism in
678 addition to major histocompatibility complex blocking. *Proceedings of the National*
679 *Academy of Sciences* **96**, 634-639 (1999).
- 680 13 Weber, M. S. *et al.* Type II monocytes modulate T cell-mediated central nervous system
681 autoimmune disease. *Nature medicine* **13**, 935 (2007).
- 682 14 Neuhaus, O. *et al.* Multiple sclerosis: comparison of copolymer-1-reactive T cell lines from
683 treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells.
684 *Proceedings of the National Academy of Sciences* **97**, 7452-7457 (2000).
- 685 15 Duda, P. W., Schmied, M. C., Cook, S. L., Krieger, J. I. & Hafler, D. A. Glatiramer acetate
686 (Copaxone®) induces degenerate, Th2-polarized immune responses in patients with
687 multiple sclerosis. *The Journal of clinical investigation* **105**, 967-976 (2000).
- 688 16 Aharoni, R. *et al.* Glatiramer acetate reduces Th-17 inflammation and induces regulatory T-

- 689 cells in the CNS of mice with relapsing–remitting or chronic EAE. *Journal of*
690 *neuroimmunology* **225**, 100-111 (2010).
- 691 17 Aharoni, R., Kayhan, B., Eilam, R., Sela, M. & Arnon, R. Glatiramer acetate-specific T cells
692 in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ.
693 *Proc Natl Acad Sci U S A* **100**, 14157-14162, doi:10.1073/pnas.2336171100 (2003).
- 694 18 Aharoni, R. *et al.* Glatiramer acetate reduces Th-17 inflammation and induces regulatory T-
695 cells in the CNS of mice with relapsing-remitting or chronic EAE. *J Neuroimmunol* **225**,
696 100-111, doi:10.1016/j.jneuroim.2010.04.022 (2010).
- 697 19 Aharoni, R., Yussim, A., Sela, M. & Arnon, R. Combined treatment of glatiramer acetate and
698 low doses of immunosuppressive drugs is effective in the prevention of graft rejection.
699 *International immunopharmacology* **5**, 23-32 (2005).
- 700 20 Aharoni, R. *et al.* Transplanted myogenic progenitor cells express neuronal markers in the
701 CNS and ameliorate disease in Experimental Autoimmune Encephalomyelitis. *Journal of*
702 *neuroimmunology* **215**, 73-83 (2009).
- 703 21 Aharoni, R. *et al.* Immunomodulatory therapeutic effect of glatiramer acetate on several
704 murine models of inflammatory bowel disease. *Journal of Pharmacology and*
705 *Experimental Therapeutics* **318**, 68-78 (2006).
- 706 22 Aharoni, R., Sonogo, H., Brenner, O., Eilam, R. & Arnon, R. The therapeutic effect of
707 glatiramer acetate in a murine model of inflammatory bowel disease is mediated by anti-
708 inflammatory T-cells. *Immunology letters* **112**, 110-119 (2007).
- 709 23 Horani, A. *et al.* Beneficial effect of glatiramer acetate (Copaxone) on immune modulation of
710 experimental hepatic fibrosis. *Am J Physiol Gastrointest Liver Physiol* **292**, G628-638,
711 doi:10.1152/ajpgi.00137.2006 (2007).
- 712 24 Bassat, E., Perez, D. E. & Tzahor, E. Myocardial Infarction Techniques in Adult Mice.
713 *Methods Mol Biol* **2158**, 3-21, doi:10.1007/978-1-0716-0668-1_1 (2021).
- 714 25 Zerwic, J. J., Ryan, C. J., DeVon, H. A. & Drell, M. J. Treatment seeking for acute myocardial
715 infarction symptoms: differences in delay across sex and race. *Nurs Res* **52**, 159-167
716 (2003).
- 717 26 Epelman, S., Liu, P. P. & Mann, D. L. Role of innate and adaptive immune mechanisms in
718 cardiac injury and repair. *Nature reviews. Immunology* **15**, 117-129, doi:10.1038/nri3800
719 (2015).
- 720 27 Aharoni, R. Immunomodulation neuroprotection and remyelination - the fundamental
721 therapeutic effects of glatiramer acetate: a critical review. *J Autoimmun* **54**, 81-92,
722 doi:10.1016/j.jaut.2014.05.005 (2014).
- 723 28 Aharoni, R. *et al.* Immunomodulatory therapeutic effect of glatiramer acetate on several
724 murine models of inflammatory bowel disease. *J Pharmacol Exp Ther* **318**, 68-78,
725 doi:10.1124/jpet.106.103192 (2006).
- 726 29 Ma, Y. Role of Neutrophils in Cardiac Injury and Repair Following Myocardial Infarction.
727 *Cells* **10**, doi:10.3390/cells10071676 (2021).
- 728 30 Santos-Zas, I., Lemarie, J., Tedgui, A. & Ait-Oufella, H. Adaptive Immune Responses
729 Contribute to Post-ischemic Cardiac Remodeling. *Front Cardiovasc Med* **5**, 198,
730 doi:10.3389/fcvm.2018.00198 (2018).
- 731 31 Puhl, S. L. & Steffens, S. Neutrophils in Post-myocardial Infarction Inflammation: Damage
732 vs. Resolution? *Front Cardiovasc Med* **6**, 25, doi:10.3389/fcvm.2019.00025 (2019).
- 733 32 Grune, J. *et al.* Neutrophils incite and macrophages avert electrical storm after myocardial
734 infarction. *Nat Cardiovasc Res* **1**, 649-664, doi:10.1038/s44161-022-00094-w (2022).

- 735 33 Averill, M. M., Kerkhoff, C. & Bornfeldt, K. E. S100A8 and S100A9 in cardiovascular
736 biology and disease. *Arterioscler Thromb Vasc Biol* **32**, 223-229,
737 doi:10.1161/ATVBAHA.111.236927 (2012).
- 738 34 Harhous, Z., Booz, G. W., Ovize, M., Bidaux, G. & Kurdi, M. An Update on the Multifaceted
739 Roles of STAT3 in the Heart. *Front Cardiovasc Med* **6**, 150, doi:10.3389/fcvm.2019.00150
740 (2019).
- 741 35 Li, J., Tan, J., Martino, M. M. & Lui, K. O. Regulatory T-Cells: Potential Regulator of Tissue
742 Repair and Regeneration. *Front Immunol* **9**, 585, doi:10.3389/fimmu.2018.00585 (2018).
- 743 36 Jee, Y. *et al.* CD4⁺ CD25⁺ regulatory T cells contribute to the therapeutic effects of glatiramer
744 acetate in experimental autoimmune encephalomyelitis. *Clinical Immunology* **125**, 34-42
745 (2007).
- 746 37 Dick, S. A. *et al.* Self-renewing resident cardiac macrophages limit adverse remodeling
747 following myocardial infarction. *Nat Immunol* **20**, 29-39, doi:10.1038/s41590-018-0272-2
748 (2019).
- 749 38 Loyer, X. *et al.* Intra-Cardiac Release of Extracellular Vesicles Shapes Inflammation
750 Following Myocardial Infarction. *Circulation research* **123**, 100-106,
751 doi:10.1161/CIRCRESAHA.117.311326 (2018).
- 752 39 Pezzana, C., Agnely, F., Bochot, A., Siepmann, J. & Menasche, P. Extracellular Vesicles and
753 Biomaterial Design: New Therapies for Cardiac Repair. *Trends Mol Med* **27**, 231-247,
754 doi:10.1016/j.molmed.2020.10.006 (2021).
- 755 40 Yadid, M. *et al.* Endothelial extracellular vesicles contain protective proteins and rescue
756 ischemia-reperfusion injury in a human heart-on-chip. *Sci Transl Med* **12**,
757 doi:10.1126/scitranslmed.aax8005 (2020).
- 758 41 Piamsiri, C., Maneechote, C., Siri-Angkul, N., Chattipakorn, S. C. & Chattipakorn, N.
759 Targeting necroptosis as therapeutic potential in chronic myocardial infarction. *J Biomed*
760 *Sci* **28**, 25, doi:10.1186/s12929-021-00722-w (2021).
- 761 42 Tallquist, M. D. & Molkenin, J. D. Redefining the identity of cardiac fibroblasts. *Nat Rev*
762 *Cardiol* **14**, 484-491, doi:10.1038/nrcardio.2017.57 (2017).
- 763 43 Talman, V. & Kivela, R. Cardiomyocyte-Endothelial Cell Interactions in Cardiac Remodeling
764 and Regeneration. *Front Cardiovasc Med* **5**, 101, doi:10.3389/fcvm.2018.00101 (2018).
- 765 44 Liu, J. *et al.* T cell independent mechanism for copolymer-1-induced neuroprotection. *Eur J*
766 *Immunol* **37**, 3143-3154, doi:10.1002/eji.200737398 (2007).
- 767 45 Narmoneva, D. A., Vukmirovic, R., Davis, M. E., Kamm, R. D. & Lee, R. T. Endothelial cells
768 promote cardiac myocyte survival and spatial reorganization: implications for cardiac
769 regeneration. *Circulation* **110**, 962-968, doi:10.1161/01.CIR.0000140667.37070.07
770 (2004).
- 771 46 Murphy, S. P., Kakkar, R., McCarthy, C. P. & Januzzi, J. L., Jr. Inflammation in Heart Failure:
772 JACC State-of-the-Art Review. *J Am Coll Cardiol* **75**, 1324-1340,
773 doi:10.1016/j.jacc.2020.01.014 (2020).
- 774 47 Zile, M. R. *et al.* Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic
775 Peptide in Patients With Heart Failure. *J Am Coll Cardiol* **68**, 2425-2436,
776 doi:10.1016/j.jacc.2016.09.931 (2016).
- 777 48 Julier, Z., Park, A. J., Briquez, P. S. & Martino, M. M. Promoting tissue regeneration by
778 modulating the immune system. *Acta Biomater* **53**, 13-28,
779 doi:10.1016/j.actbio.2017.01.056 (2017).
- 780 49 Vagnozzi, R. J. *et al.* An acute immune response underlies the benefit of cardiac stem cell

- 781 therapy. *Nature* **577**, 405-409, doi:10.1038/s41586-019-1802-2 (2020).
- 782 50 Miettinen, K. H. *et al.* Prognostic role of pro- and anti-inflammatory cytokines and their
783 polymorphisms in acute decompensated heart failure. *Eur J Heart Fail* **10**, 396-403,
784 doi:10.1016/j.ejheart.2008.02.008 (2008).
- 785 51 Jensen, J. *et al.* Inflammation increases NT-proBNP and the NT-proBNP/BNP ratio. *Clin Res*
786 *Cardiol* **99**, 445-452, doi:10.1007/s00392-010-0140-z (2010).
- 787 52 Ziemssen, T., Ashtamker, N., Rubinchick, S., Knappertz, V. & Comi, G. Long-term safety and
788 tolerability of glatiramer acetate 20 mg/ml in the treatment of relapsing forms of multiple
789 sclerosis. *Expert Opin Drug Saf* **16**, 247-255, doi:10.1080/14740338.2017.1274728
790 (2017).
- 791 53 Ford, C. *et al.* Continuous long-term immunomodulatory therapy in relapsing multiple
792 sclerosis: results from the 15-year analysis of the US prospective open-label study of
793 glatiramer acetate. *Mult Scler* **16**, 342-350, doi:10.1177/1352458509358088 (2010).
- 794 54 Miller, A., Spada, V., Beerkircher, D. & Kreitman, R. R. Long-term (up to 22 years), open-
795 label, compassionate-use study of glatiramer acetate in relapsing-remitting multiple
796 sclerosis. *Mult Scler* **14**, 494-499, doi:10.1177/1352458507085029 (2008).
- 797 55 Braenne, I. *et al.* Genomic correlates of glatiramer acetate adverse cardiovascular effects lead
798 to a novel locus mediating coronary risk. *PLoS One* **12**, e0182999,
799 doi:10.1371/journal.pone.0182999 (2017).
- 800 56 Januzzi, J. L., Jr. *et al.* Prognostic Importance of NT-proBNP and Effect of Empagliflozin in
801 the EMPEROR-Reduced Trial. *J Am Coll Cardiol* **78**, 1321-1332,
802 doi:10.1016/j.jacc.2021.07.046 (2021).
- 803 57 Tzahor, E. & Dimmeler, S. A coalition to heal-the impact of the cardiac microenvironment.
804 *Science* **377**, eabm4443, doi:10.1126/science.abm4443 (2022).
- 805 58 Bassat, E. *et al.* The extracellular matrix protein agrin promotes heart regeneration in mice.
806 *Nature* **547**, 179-184, doi:10.1038/nature22978 (2017).
- 807 59 Wu, Y., Yin, X., Wijaya, C., Huang, M. H. & McConnell, B. K. Acute myocardial infarction
808 in rats. *J Vis Exp*, doi:10.3791/2464 (2011).
- 809 60 Thery, C. *et al.* Minimal information for studies of extracellular vesicles 2018 (MISEV2018):
810 a position statement of the International Society for Extracellular Vesicles and update of
811 the MISEV2014 guidelines. *J Extracell Vesicles* **7**, 1535750,
812 doi:10.1080/20013078.2018.1535750 (2018).
- 813 61 Alvarez, R., Jr. *et al.* Cardiomyocyte cell cycle dynamics and proliferation revealed through
814 cardiac-specific transgenesis of fluorescent ubiquitinated cell cycle indicator (FUCCI).
815 *Journal of molecular and cellular cardiology* **127**, 154-164,
816 doi:10.1016/j.yjmcc.2018.12.007 (2019).
- 817 62 Redfors, B., Shao, Y. & Omerovic, E. Myocardial infarct size and area at risk assessment in
818 mice. *Exp Clin Cardiol* **17**, 268-272 (2012).
- 819 63 Ali, M. A., Kandasamy, A. D., Fan, X. & Schulz, R. Hydrogen peroxide-induced necrotic cell
820 death in cardiomyocytes is independent of matrix metalloproteinase-2. *Toxicol In Vitro* **27**,
821 1686-1692, doi:10.1016/j.tiv.2013.04.013 (2013).
- 822 64 Gavert, N. *et al.* Ex vivo organotypic cultures for synergistic therapy prioritization identify
823 patient-specific responses to combined MEK and Src inhibition in colorectal cancer. *Nat*
824 *Cancer* **3**, 219-231, doi:10.1038/s43018-021-00325-2 (2022).
- 825 65 Sarig, R., Baruchi, Z., Fuchs, O., Nudel, U. & Yaffe, D. Regeneration and transdifferentiation
826 potential of muscle-derived stem cells propagated as myospheres. *Stem Cells* **24**, 1769-

827 1778 (2006).

828

829 **Acknowledgments**

830 We thank Ishai Sher from the Graphic Department at Weizmann Institute for excellent graphic
831 assistance; Marina Cohen from the Histology unit at Weizmann Institute; Yishai Levin and Corine
832 Katina from the Proteomic Unit of the Grand Israel National Center for Personalized Medicine, at
833 Weizmann Institute; Galina Levin, Larisa Kogan and Lilian Abu-Heichel for coordinating the
834 clinical trial in Hadassah Medical Center; Oliana Vazhgovsky for coordinating the biopsies
835 transfer from Sheba Medical Center.

836

837 **Funding:**

838 The study was supported by the following funding sources:

839 European Research Council, ERC AdG grant no. 788194, CardHeal (E.T)

840 ERC-PoC no. 899224, ReDHeaD (E.T)

841 EU Horizon 2020 Research and Innovation Programme REANIMA

842 **Author contributions:**

843 Conceptualization: R.S, E.T, G.A, O.A, K.U

844 Methodology: R.S, E.T, G.A, O.A, R.A, K.U, Ru.A, Ri.A

845 Investigation: G.A, J.E, K.U, H.B, R.S, S.M, D.L, D.K, U.K, D.N, M.A, D.M, T.S,

846 L.Z, Z.P

847 Funding acquisition: E.T

848 Supervision: E.T, R.S

849 Writing – original draft: E.T, R.S, G.A

850 Writing – review & editing: O.A, R.A

851 **Competing interests:** The authors vouch no competing interests.

852 **Data and materials availability:** Raw data of proteomic analysis will be provided at later
853 stages.

854

855

856

857

858

859

860

861

862

863

864

865


866

867

868


869

870 **FIGURES**



871

872 **Figure 1: Glatiramer acetate improves mouse cardiac function after myocardial infarction.**
873 **A**, A scheme of the experimental procedure. Mice were divided into two groups receiving either
874 GA (2 mg/animal/day) or control (PBS / mannitol) by daily IP injections, from day 0 (day of MI)
875 up to 14 days post-MI. Echo measurements were performed at baseline (2 days before MI) and at
876 2-, 14- and 35-days post-MI. Histological analysis was performed postmortem. **B,C**,
877 Echocardiographic measurements of ejection fraction (EF, **B**) and fractional shortening (FS, **c**) at
878 baseline, 2 days and 35 days after panels). The percent reduction in EF or FS is shown on the right
879 ($n_{\text{control}} = 13$, $n_{\text{GA}} = 20$). **D**, Masson's trichrome staining of heart sections derived from
880 representative PBS- (Ctrl, top) or GA-treated hearts (bottom). **E**, Left: Mean percentage of scar
881 area in sections from GA- or control-treated hearts 35 days after MI. Right: Scar stratification
882 according to size reveals that large scars (>30% of LV) were found only in the control group. **F**,
883 representative sections of control (upper row) and GA-treated (lower row) hearts, showing well
884 perfused myocardium (black), IAAR (dashed *yellow* line) and IZ (dashed *white* line). **G**,
885 Quantification of % IAAR/LV showing no significant differences between the groups, while %
886 IZ/IAAR and %BZ/IAAR demonstrate a significant reduction in IZ following GA treatment and
887 increase in BZ, suggesting myocardial protection ($n_{\text{GA}} = 4$, $n_{\text{control}} = 3$). IAAR = ischemic area-at-
888 risk, IZ = infarct zone, BZ = border zone. **H**, A wide temporal therapeutic window for GA is shown
889 by echo measurements of EF (upper) and FS (lower) in animals treated with PBS (control) or GA
890 at the day of injury, 24- or 48-hours post-MI. $n_{\text{control}} = 9$, $n_{\text{GA}/t0} = 16$, $n_{\text{GA}/24h} = 7$, $n_{\text{GA}/48h} = 5$.
891



892

893

894 **Figure 2: GA treatment promotes a pro-reparative immune phenotype**

895 **A**, Experimental design. Sample size – 1 dpi ($n_{GA} = 1$, $n_{Control} = 1$), 4 dpi ($n_{GA} = 2$, $n_{Control} = 2$). **B**,
896 EF values at baseline and 3 dpi, demonstrating a cardiac protective effect induced by GA treatment.
897 **C**, Dimensional reduction with UMAP. **D**, Frequency plots of specific cell types according to days.
898 **E**, Neutrophilic cluster, **F**, Heatmap of DEG between GA and control at 1 dpi. Adjusted P -value
899 <0.05 . **G**, A violin plot for canonical markers for neutrophil activation. **H**, IPA performed on DEG
900 of neutrophil cluster at 1 dpi. **I**, FACS analysis measuring the percentage of myeloid cells and
901 neutrophils in control versus GA-treated mice 24h after MI ($n_{control} = 5$, $n_{GA} = 6$). **J**, Levels of pro-
902 inflammatory mediators IL- α and CCL-2 were measured 24h post-MI in serum by ELISA. Levels
903 are shown as fold-change from uninjured mice. $n_{GA} = 4$, $n_{mannitol} = 4$, $n_{sham} = 3$. **K**, highlights of T
904 cells and Timd4⁺ resident macrophages. **L**, IPA performed on DEG of T cells and Timd4⁺
905 macrophages on respective clusters of CD45⁺ cell subset (adjusted P value <0.05). **M**, *upper*
906 *panel*: FACS analysis of Timd4⁺ macrophages in GA-treated hearts 4 dpi ($n_{mannitol} = 5$, $n_{GA} = 4$)
907 and Foxp3⁺ Tregs in GA-treated hearts 7 dpi ($n = 5$ for each group). *Lower panel*: Representative
908 heart sections derived from GA- or PBS-treated mice 7 dpi that were co-immunostained with anti-
909 CD3 and anti-Foxp3. Scale bars: 60 μ m.

910

911


912

913


914

915

916



939 **Figure 3: The protective effect of glatiramer acetate is mediated by extracellular vesicles.**
940 **A**, Representative M-mode echocardiography images, at 3 dpi. **B**, Analysis of echocardiographic
941 systolic parameters. **C**, PCA of proteomic data. **D**, Heatmap of differentially expressed proteins
942 (n=3 in each group). **E**, Gene ontology terms and pathway analysis. Arrow points to extracellular
943 exosomes pathway. **F**, A graphical illustration of EV experiments (n=16). **G**, Representative M-
944 mode echocardiography images, at 3 dpi. **H**, EF measurements (left), comparing the three
945 experimental groups at baseline and 3 dpi. The right panel shows the change in EF as a fold-change
946 from baseline levels. **I**, Masson Trichrome representative cardiac sections (left) and IF images
947 (right) demonstrate smaller infarcts with large areas of viable myocardium, as well as higher
948 density of α SMA+ blood vessels (arrowheads) in mice treated with GA-derived EVs. Scale bars:
949 left panels, 750 μ m; right panels, 120 μ m. **J,K**, Analysis of infarct size (n=15) (**J**), and blood vessel
950 density (n=6) (**K**) at 4 dpi. **L**, Proteomic analysis of cardiac EVs. Unsupervised PCA showing 3
951 distinct clusters of the experimental groups. **M**, ANOVA results of differentially expressed
952 proteins between GA-derived and control-derived EVs. **N**, Gene ontology terms and pathway
953 analysis, ranked according to $-\log_{10}(\text{corrected-p-value})$. **O**, targeted heatmap of individual
954 proteins comprising key differentially changed pathways. Statistical significance was calculated
955 using a two-tailed *t*-test, or ANOVA with Tukey's correction for multiple comparisons, as
956 appropriate.



957

958 **Figure 4: Glatiramer acetate exerts pleiotropic beneficial effect on the injured heart.**

959 **A**, Representative heart sections showing scar analysis (left) and TUNEL assay in the border-zone

960 24h after injury. Scale bars: middle panels, 200 μ m; right panels, 400 μ m. **B**, Higher magnifications


961 showing TUNEL positive cells in CMs. Scale bar: 75 μ m. **C,D**, Quantification of percentage of

962 apoptotic nuclei in CMs at 24h (C) and 96h (D) post-MI ($n_{\text{control}}=4$; $n_{\text{GA}}=3$, an average of 458

963 cells were counted for each group). **E**, Representative heart sections showing scar analysis (left)

964 and TUNEL assay in the border-zone 96h after injury. Scale bars: 200 μ m. **F**, Representative heart

965 sections derived from control and GA-treated hearts, stained with anti-vimentin (24h) or anti-
966 vimentin with anti-Ki67 (96h) in the border-zone. Scale bars: left, 400 μm ; right, 120 μm . **G**,
967 Quantification of proliferating CFs at 4dpi ($n_{\text{GA}} = 4$, $n_{\text{control}} = 3$). 1658 and 736 cells were counted
968 for GA and PBS, respectively. **H**, Quantification of capillaries observed in the injured area,
969 normalized to the scar area ($n_{\text{PBS}} = 5$, $n_{\text{GA}} = 4$). **I**, Representative heart sections derived from GA-
970 or PBS- treated mice at 14 dpi, showing capillary formation in the scar area. Right panels show
971 higher magnification of the left panels. Scale bars: left panels, 750 μm ; right panels, 150 μm . **J**,
972 Representative heart sections derived from GA- or PBS-treated mice at 14 dpi, showing scar area
973 (left panels), and SMA+ blood vessels (right panels). Scale bars: 120 μm . **K**, Quantification of
974 blood vessels observed in the injured area, normalized to the scar area ($n=3$ for each group).




975

976 **Figure 5: Glatiramer acetate has beneficial effects on cultured cardiac cells.**

977 **A**, TUNEL assay in P3 cardiac cultures treated either with STS alone or with STS and GA. (n=3,
978 PBS = 4,700, GA = 1321 cells). Scale bars: 150 μm. **B**, DAPI exclusion assay at 48h after
979 treatment. Quantification of surviving CMs per area square (right). Scale bars: 150 μm. **C**, DAPI
980 exclusion assay after challenge with H₂O₂. Quantification of the fold-change in cTnI+DAPI+ dead


981 CMs between the two groups (right) (n = 5, 2500 cells). Scale bars: 300 μ m. **D**, P3 cultures were
982 treated with FITC-GA stained with the indicated antibodies. Scale bars: upper left, 300 μ m; lower
983 left and right panels, 150 μ m. **E**, EVOC treated with FITC-GA show its accumulation in interstitial
984 cells. **F**, Representative fields show a large colony of ECs in GA-treated cultures, whereas in
985 control cultures CD31+ cells were dispersed. Scale bars: 300 μ m. **G**, Quantification of
986 proliferating ECs (n=3 for each group, 678 and 1704 cells for the control and GA, respectively).
987 **H**, IF stain of P3 cultures 14 days following treatment with GA. Scale bars: left, 300 μ m; right,
988 150 μ m. **I**, qRT-PCR analysis of CD31 and cTnI in the cultures described in H.



989

990 **Figure 6: Transient treatment with glatiramer acetate improves heart function in a rat model**
 991 **of heart failure.**

992 **A**, A scheme of the experimental procedure. **B**, Representative echocardiographic loops of short
993 axis view at baseline (left, <https://youtu.be/k58RMQJ1ed4> and 21 dpi (right,
994 <https://youtu.be/6m3PJscTPJc>) **C**, Relative mRNA expression of *Nppb* (n=3, left panel), and
995 echocardiographic measurement of LVID in diastole at baseline and 21 dpi (n=23, right panel). **D**,
996 Representative images using the M-Mode configuration. **E,F**, Echocardiographic measurements
997 of EF (E) and FS (F) parameters in hearts that were treated with GA compared to control hearts.
998 Grey area marks the period of injections. **G,H**, Graphs showing the individual (left) and mean
999 (right) differences in EF (G) and FS (H) parameters between 21- and 120-days post-injury. **I**, The
1000 mean % difference in LVID in diastole at 120 dpi between animals treated with control (left, red)
1001 and GA (right, blue) ($n_{\text{control}} = 11$, $n_{\text{GA}} = 12$). **J**, Echocardiographic measurements of the LV volume
1002 in systole ($n_{\text{control}} = 11$, $n_{\text{GA}} = 12$). **K**, representative images of histological sections comparing
1003 interstitial fibrosis at the beginning of treatment (21d) and at end-point (120d), together with the
1004 quantification (right) ($n_{21\text{d}} = 9$, $n_{\text{control}} = 5$, $n_{\text{GA}} = 6$).
1005



1006

1007 **Figure 7: Glatiramer acetate reduces the cytokine surge and serum levels of NT-proBNP in**
 1008 **patients with acute decompensated heart failure.**

1009 **A,B,** Trial design. Patients admitted to the hospital with ADHF were screened over 48h. Eligible

1010 patients were assigned to receive only GDMT or GDMT with GA as an add-on therapy for 14

1011 days. Repeat clinical follow up and blood sample analysis of cytokines and cardiac biomarkers
1012 were performed at the indicated time points. **C**, Baseline values of parameters associated with the
1013 primary (selected cytokines) and secondary (NT-proBNP) endpoints. Continuous variables are
1014 presented as median and interquartile range (IQR), discrete variables as proportions. **D**, Primary
1015 endpoint - GA blunts the cytokine surge in patients with ADHF. A logarithmic scale of the mean
1016 pooled results for each cytokine at days 2 and 14, normalized to baseline levels. A significant
1017 general silencing of the cytokine surge is detected in the GA-treated group of patients. **E**, Separate
1018 values of representative cytokines showing significant changes the GA-treated group. **F**,
1019 Secondary endpoint - GA treatment significantly reduced serum levels of NT-proBNP, the levels
1020 of which are presented as fold-change from baseline (left) and as raw values on a logarithmic scale
1021 (right). **G**, A scatter plot showing the fold-change in NT-proBNP levels as a function of different
1022 serum cytokines, transformed on a logarithmic scale. The GA-treated group (in blue) is clustered
1023 on the bottom left, reflecting low levels of both cytokines and NT-proBNP, as opposed to control
1024 group (in red), clustered on the top right, reflecting high inflammation and NT-proBNP levels.

1025

1026 **List of Supplementary Materials**

1027 Supplementary Materials and Methods

1028 Fig. S1 to S10

1029 Supplementary Tables 1-2

1030

1031

1032

1033

1034 **Supplementary Materials**

1035

1036 **Supplementary materials and methods**

1037 **Glatiramer acetate.** Two types of GA were used for the experiments: either powder or Copaxone
1038 syringes (both from Teva), with proper controls for each type. PBS was used to dissolve the
1039 powder, whereas mannitol was the solvent of Copaxone syringes. The potency of the two GA
1040 preparations was very similar in all the described experiments. For the *in vivo* experiment, we used
1041 a well-established concentration of 2 mg/100 μ l, which was shown to be effective for the treatment
1042 of EAE mice^{9,10}. The concentration used for the *in vitro* experiments was 20-30 μ g/ml. A Protein
1043 FITC Labeling Kit (EZLabel™, K832-5, BioVision Inc., USA) was used to produce a FITC-
1044 conjugated GA, according to the manufacturer's instructions.

1045 **Scar quantification.** Scarred tissue was quantified by performing Masson's trichrome staining on
1046 serial cardiac sections spanning the entire left ventricle using ImageJ. The area of scar (blue) and
1047 LV were calculated and summed from all sections in order to obtain true scar volume normalized
1048 to LV myocardial volume.

1049 **Blood vessel and endothelial cell density.** Capillary and blood vessel density were calculated by
1050 measuring CD31+ area and counting α SMA+ blood vessels in scar tissue, respectively, normalized
1051 to scar area. Area measurements were performed using ImageJ.

1052 **Assessment of ischemic area-at-risk and infarct zone.** Assessment of IAAR was performed as
1053 previously published⁶² with modifications. Briefly, At the 4th day after permanent LAD ligation,
1054 animals were anesthetized using CO₂ inhalation. Demarcation of ischemic area-at-risk was
1055 achieved by performing *in situ* antegrade perfusion using 8 mL of black dye through ventricular
1056 apical canulation. Subsequently, hearts was excised from the chest, washed twice in ice-cold PBS

1057 and transferred to -20°C for 8 minutes. Hearts were then axially sectioned using a razor blade, at
1058 200 μm intervals. For delineating infarct zone, the myocardial sections were subsequently
1059 incubated at room temperature in 2% triphenyltetrazolium chloride (Sigma-Aldrich, T8877) for 10
1060 minutes, after which the sections were washed twice with PBS. Sections were imaged using a
1061 stereomicroscope (Carl Zeiss Stemi 305cam Binocular). Quantification of ARR and IZ were
1062 performed using ImageJ, and normalized to LV where appropriate.

1063 **Sample and libraries preparation for scRNA-seq.** Single-cell RNA-seq libraries were prepared
1064 at the Crown Genomics Institute of the Nancy and Stephen Grand Israel National Center for
1065 Personalized Medicine, Weizmann Institute of Science using the 10X Genomics technology.
1066 Tissue was dissociated into single-cell suspension using a neonatal dissociation kit (Miltenyi
1067 Biotec, 130-098-373) and the gentleMACS homogenizer, according to the manufacturer's
1068 instructions. Briefly, animals were sacrificed, and the hearts were perfused in situ using ice-cold
1069 PBS solution. Subsequently the hearts were excised from the body and washed twice in PBS. The
1070 atria and right ventricle were removed to enrich for LV tissue. The LV-enriched tissue was minced
1071 to small pieces using fine scissors. The tissue was transferred to a gentleMACS C-tube (130-093-
1072 237) and dissociation was carried according to the protocol. Enrichment for CD45⁺ cells was
1073 achieved using CD45 MicroBeads enrichment protocol (Miltenyi Biotec, 130-052-301). Briefly,
1074 CD45⁺ cells were magnetically labeled with CD45 MicroBeads. Positive selection of immune
1075 cells was achieved by mounting the labeled suspension on a MACS Column, placed in a magnetic
1076 field of a MACS Separator. Cells were counted and viability was assessed using trypan blue and a
1077 hemocytometer. Cells were diluted in PBS + 0.04% BSA to a final concentration of 1000 cells/ μl
1078 and immediately processed with the Chromium Next GEM Single Cell 3' v3.1 kit, according to
1079 the manufacturer protocol. Final libraries were quantified by qPCR with the NEB-next Library

1080 Quant Kit (New England Biolabs), as well as with Qubit and TapeStation. Sequencing was done
1081 on a Nova-Seq6000 using SP, 100 cycles kit mode allocating 800M reads in total (Illumina). Fastq
1082 files were generated by the usage of bcl2fastq v2.20.0.422.

1083 **Bioinformatic analysis**

1084 CellRanger pipeline (Zheng et al., 2017) (v7.0.1, 10× Genomics) with default settings was used
1085 for alignment (mm10 reference genome, 2020-A version, downloaded from 10× Genomics
1086 website), filtering, barcode counting and UMI (Unique Molecular Identifier) counting. The R
1087 Seurat package (Satija et al., 2015) (v4.0.4) was used for quality control, dimensionality reduction,
1088 visualization, and analysis. Low-quality cells were excluded based on the following criteria:
1089 having fewer than 250 genes, fewer than 500 UMIs, and exceeding 4 MAD (median absolute
1090 deviation) the median for genes, UMIs, and mitochondrial reads. Additionally, genes expressed in
1091 less than 10 cells were eliminated from the analysis. After implementing these quality control
1092 measures, a total of 49,369 cells (from all samples) and 21,031 genes were retained for further
1093 analysis (control dpi 1: 3016, GA dpi 1: 3537, control dpi 4: 24431, GA dpi 4: 18,385).

1094 Merged counts matrix was log-normalized using the NormalizeData function. The 2,000 highly
1095 variable genes were identified using the FindVariableFeatures function with the ‘vst’ method. Data
1096 was scaled with the ScaleData function. Principal component analysis (PCA) was performed.
1097 Seurat's unsupervised graph-based clustering and uniform manifold approximation (UMAP) were
1098 conducted on the projected principal component (PC) space.

1099 Marker genes for each cluster were determined with the non-parametric Wilcoxon rank sum test
1100 by FindAllMarkers function. Those with a $\log_{2}FC > 0.5$ and expressed in at least 50% of the cells
1101 were selected as significant marker genes. Cell types were identified based on the expression of
1102 classic marker genes. Cells were represented by a total of 19 clusters including monocytes and

1103 macrophages (*Cd68+Itgam+*), neutrophils (*S100a9+S100a8+*), T cells (*Cd3e+Cd3d+*), B cells
1104 (*Cd79aMs4a1+*), endothelial cells (*Kdr+Pecam1+*), fibroblasts (*Colla1+Dcn+*), myofibroblasts
1105 (*Colla1+Postn+*), pericytes (*Rgs5+Abcc9+*) and smooth muscle cells (*Acta2+Myh11+*) (Fig.
1106 2C). Visualization used Seurat's FeaturePlot, DotPlot and VlnPlot functions.

1107 FindMarkers was used to identify DE genes between different clusters. Those with a $p_val_adj <$
1108 0.05 were considered to be significant and taken for further analysis using IPA (Ingenuity®
1109 Systems, www.ingenuity.com) or DAVID analysis tool.

1110 **Bulk proteomic analysis.** Cardiac samples of proteomic analysis were processed as previously
1111 published⁵⁸. Hearts were removed 4 days post-MI and briefly perfused with ice-cold PBS. The
1112 left ventricle was dissected and snap-frozen in liquid nitrogen. Samples were crushed to a fine
1113 powder, intermittently maintaining nitrogen cooling, and transferred into a lysis buffer consisting
1114 of 5% SDS and 50 mM Tris (pH 7.4) for thorough homogenization using a drill. The samples were
1115 centrifuged at 5000 g for 15 sec and boiled at 96°C for 15 min. After further centrifugation at
1116 maximal speed for 2 min, the supernatant was collected, and protein concentrations were
1117 quantified by BCA assay (Thermo Fisher, 23225). For LC-MS and data processing, samples were
1118 lysed with urea and subjected to in-solution tryptic digestion, followed by a desalting step. The
1119 resulting peptides were analyzed using Waters HSS-T3 column on nanoflow liquid
1120 chromatography (nanoAcquity) coupled to high resolution, high mass accuracy mass spectrometry
1121 (Fusion Lumos). Thresholds used were p-value <0.05 , fold-change >2 , and at least 2 peptides
1122 detected on mass spectrometry. Gene ontology (GO) terms and pathway analysis performed using
1123 DAVID Analysis Tool.

1124 **ROS assay.** ROS assays were performed as previously published with modifications⁶³. P3 primary
1125 cultures were treated with either 30 $\mu\text{g/ml}$ GA, PBS, or conditioned media for 3 days. On the third

1126 day of treatment, the cells were challenged with 1 μ M H₂O₂ (Sigma, 7722-84-1) or a similar
1127 volume of PBS for 2 h, after which the wells were washed twice with warm PBS. For DAPI
1128 exclusion assay, 0.5 μ g/mL DAPI (Sigma, Cat. no. D9542) was added to the media for 10 min.
1129 Cells were subsequently washed with PBS and fixated in 4% PFA followed by
1130 immunofluorescence staining.

1131 **RT-qPCR.** RNA from whole hearts or cultured cells was isolated using a NucleoSpin kit
1132 (Machery Nagel, 740955.50) according to the manufacturer's instructions. A High capacity cDNA
1133 reverse transcription kit (Applied Biosystems, 4374966) was used to reverse transcribe 1 μ g of
1134 purified RNA according to the manufacturer's instructions. The quantitative PCR reactions were
1135 performed using a Fast SYBR Green PCR master mix (Thermo Fischer Scientific, 4385614) on a
1136 StepOnePlus Real-Time PCR system (Applied Biosystems). Values for specific genes were
1137 normalized to *Hprt* housekeeping control.

1138 **TUNEL assay.** Apoptotic cell death of both cell cultures and cardiac sections was measured using
1139 the ApopTag® Red *In Situ* Apoptosis Detection Kit (S7165, Merck), according to the
1140 manufacturer's instructions. Staurosporine (1 μ M, Sigma-Aldrich) or DMSO were added to
1141 cardiac cultures together with either 20 μ g/ml GA or PBS for 18 h.

1142 **Ex vivo organ cultures (EVOC).** EVOC were prepared according to Gavert *et al.*,⁶⁴ with
1143 modification for heart samples. Adult mice were euthanized, and their hearts were placed in ice-
1144 cold PBS. The fresh heart tissues were then filled with a 3.5% (w/v) low melting agarose
1145 preparation media sliced into 280- μ m-thick slices using a vibratome (Leica VT1000 S). Heart
1146 slices were cultured in growth media with GA or Mannitol for 48h, followed by treatment with 0.1
1147 μ M H₂O₂ for 4h. Slices were fixed, embedded in paraffin, and 5 μ m slices were used for TUNEL
1148 assay and IF staining.

1149 **Cytokine measurements.** Plasma and tissue protein levels were measured using a multiplex
1150 ELISA kit (mouse cytokine array GSM-CYT-1, RayBiotech, GA, USA) according to the
1151 manufacturer's protocol. In brief, blood was drawn from the retro-orbital venous plexus using
1152 glass pipettes pre-washed with 500 U/ml of heparin. Samples were centrifuged at 1200 rpm for 10
1153 min at 4°C and plasma was transferred into new tubes and kept at -80°C. For tissue protein
1154 analysis, LV tissue was dissected from the whole heart and snap-frozen in liquid nitrogen. Frozen
1155 samples were crushed with a mortar and pestle and subsequently homogenized with a drill. Total
1156 cell lysates were isolated using RIPA buffer supplemented with 1:100 protease (Sigma, P8340)
1157 and 1:100 phosphatase inhibitor cocktails (Sigma, P5726 and P0044). Protein concentrations were
1158 measured by BCA assay (Thermo Fisher, 23225). To each well, 750 µg/mL of tissue protein
1159 extract or 1:2 diluted plasma were added and incubated overnight at 4°C with blocking solution.
1160 On the following day, the samples were washed and incubated with biotinylated antibody cocktail
1161 and a secondary Cy3 equivalent dye-streptavidin. The slides were read by the RayBiotech array
1162 scanning service and data were analyzed using Piezoarray Software, version 1.1.0.0016.

1163 **EV-enriched serum from patients.** Enrichment for human EVs was performed from patients'
1164 sera using similar protocols. Subsequently, the sera were analyzed using the standard methods for
1165 EV detection: NTA, EM and verification of EV-specific markers using mass spectrometry.

1166 **Bulk RNA-seq.** For RNA-seq, GA- and control-treated hearts were collected 24 h after MI, and
1167 RNA samples were purified using the miRNeasy kit (1038703, Qiagen) according to the
1168 manufacturer's instructions. Sequencing libraries were prepared using the RNA-seq protocol of
1169 the Nancy and Stephen Grand Israel National Center for Personalized Medicine (G-INCPM),
1170 Weizmann Institute of Science. Single-end short reads were sequenced on Illumina NextSeq
1171 machine. Sequencing libraries were constructed with barcodes to allow multiplexing of the

1172 samples, yielding a median of ~25 million single-end reads per sample. Briefly, total RNA was
1173 fragmented followed by reverse transcription and second-strand cDNA synthesis. The double-
1174 strand cDNA was subjected to end repair, A base addition, adapter ligation and PCR amplification
1175 to create libraries. Libraries were evaluated by Qubit and TapeStation. For RNA analysis, adapters
1176 were trimmed using the cutadapt tool. Resulting reads shorter than 30 bp were discarded. Reads
1177 were mapped to the *Mus musculus* reference genome GRCm38 using STAR, supplied with gene
1178 annotations downloaded from Ensembl, with EndToEnd option and
1179 outFilterMismatchNoverLmax set to 0.04. Expression levels for each gene were quantified using
1180 htseq-count, using the gtf above. Differentially expressed genes were identified using DESeq2
1181 with the betaPrior, cooksCutoff and independentFiltering parameters set to False. Raw p-values
1182 were adjusted for multiple testing using the Benjamini and Hochberg procedure. Pipeline was run
1183 using snakemake .

1184 **Human cardiac cultures.** Cardiac biopsy specimens were obtained from patients with a diagnosis
1185 of tetralogy of Fallot (TOF), undergoing an open-heart surgery. Tissue explants were kept on ice
1186 until processed and were mechanically minced into 1-mm³ pieces. The cardiac human cells were
1187 isolated using a neonatal dissociation kit (Miltenyi Biotec,130-098-373) and the gentleMACS
1188 homogenizer, according to the manufacturer's instructions. The study was conducted according to
1189 the guidelines of the Declaration of Helsinki and approved by the Institutional Review Boards of
1190 Sheba Medical Center.

1191 **Immunofluorescence staining.** *Tissue cultures:* cells were fixed with 4% PFA in PBS for 10 min
1192 and permeabilized with 0.2% Triton X-100 in PBS for 5 min, followed by blocking with PBS
1193 containing 0.1% Triton X-100 and 3% bovine serum albumin for 1 h at room temperature.

1194 Immunostaining was performed as previously described⁵⁸. *Cardiac sections*: paraffin-embedded
1195 hearts were sectioned, deparaffinized and stained as above with the addition of an antigen retrieval
1196 step that was performed in 10 mM citric acid, (pH 6.0) or 0.1 M Tris-EDTA buffer (pH 9.0).
1197 Images were obtained with a Nikon Eclipse Ti2 fluorescent microscope with the Nikon's NIS-
1198 Elements software. Primary antibodies: anti-pHistone 3 (pH3, ab47297 ABCAM 1:1000), anti-
1199 Ki67 (Cell Marque #275R, 1:200), anti-cTnT (Abcam, ab33589, 1:200 or CT3 hybridoma product,
1200 DSHB by Lin, J.J.-C., 1:10), anti-cTnI (Abcam, ab47003, 1:200 or TI-4 hybridoma product, DSHB
1201 by Schiaffino, S., 1:10), anti-CD31 (Abcam, ab28364, 1:200), anti-Vimentin (Abcam, ab24525,
1202 1:200). SMA (Sigma, A2547, 1:400), anti-Foxp3 (Invitrogen, FJK-16S, 1:100), anti-CD3 (Abcam,
1203 ab16669, 1:150).

1204 **FACS.** Hearts were perfused with 10 ml of ice-cold PBS and left ventricles were dissected and
1205 digested in RPMI containing Collagenase-I (Sigma, 450 U/ml), Collagenase-XI (Sigma,
1206 120U/ml), Hyaluronidase (Sigma, 60 U/ml) and DNase-I (Sigma, 10 mg/ml) at 37°C for 1 h, while
1207 agitated at 200 rpm. Digested materials were passed through a 120- μ m metal mesh into 12 ml PBS
1208 and pelleted by cooled centrifugation (4°C, 1400 rpm, 5 min). Supernatant was removed and the
1209 pellet was resuspended in 3 ml of MACS buffer (2% FBS, 1 mM EDTA in PBS), followed by
1210 additional centrifugation (4°C, 1400 rpm, 5 min). Samples were blocked in 50 μ l of anti-CD16/32
1211 antibodies (clone: 93, 1:200) for 20 min at 4°C, resuspended in 3 ml MACS buffer and centrifuged
1212 (4°C, 1400 rpm, 5 min). Cells were incubated in antibody mixture (50 μ l) in MACS buffer for 20
1213 min at 4°. Samples were washed in 3 ml MACS buffer containing DAPI (0.5 μ g/mL) and
1214 centrifuged (4°C, 1400 rpm, 5 min). Single-cell suspension was resuspended in 0.5 ml of MACS
1215 buffer and filtered through 40- μ m mesh prior to FACS analysis by Fortessa (BD Biosciences, BD
1216 Diva Software). For intracellular staining, cells were processed as described above with the

1217 following changes: after primary antibody incubation, cells were washed in MACS buffer and
1218 centrifuged (4°C, 1400 rpm, 5 min), followed by fixation using 1 mL of True-Nuclear™
1219 (BioLegend, cat# 424401) for 18h at 4°C. Cells were processed further according to the True-
1220 Nuclear™ manufacturer protocol. Prior to FACS analysis, cells were resuspended in 0.5 ml MACS
1221 buffer. Data were analyzed using the FlowJo (v10.6.2) software. *Antibodies* (all from BioLegend):
1222 CD45 (clone: 30-F11 , 1:100), CD11b (clone: M1/70, 1:200), CD4 (clone: GK1.5, 1:100), TCRb
1223 (clone: H57-597, 1:100), FOXP3 (clone: MF-14, 1:100), LY6G (clone: 1A8, 1:100), LY6C (clone:
1224 HK1.4, 1:100), GR1 (Ly6C+, Ly6G+, clone: RB6-8C5, 1:100), F4/80 (1:80), Tim-4 (clone: F31-
1225 5G3, 1:100), CCR2 (clone: SA203G11, 1:100). *Gating for FACS*: Myeloid cells: DAPI-
1226 CD45+CD11b+; neutrophils: DAPI-CD45+CD11b+Ly6g+ cells, further parsed by LY6C; T-
1227 regulatory cells: DAPI-CD45+CD11b-TCRb+CD4+, further parsed by FOXP3; resident
1228 macrophages: DAPI-CD45+CD11b+F4/80+ GR1- (Ly6c+,Ly6G+), further parsed by
1229 TIMD4+CCR2-.

1230 **Conditioned media.** P3 primary cultures were seeded on 96-well plates (Nuncio, 167008) at a
1231 density of 50,000-60,000 cells/well. We used the pre-plating technique to exclude CMs⁶⁵, by
1232 washing the cultures 3 h after isolation and growing only the adherent cells, which were mainly
1233 CFs, myofibroblasts and ECs. Two days afterwards, the cells were incubated with either mannitol
1234 or 30 µg/ml GA for 10 h, after which they were washed twice with PBS to discard all residual GA
1235 and incubated in fresh medium. The medium was collected after 12 h, passed through a 0.22-µm
1236 cell strainer (Durapore Membran, SLGV033R, Merck Millipore, Cork, IRL) and kept at -20°C
1237 until use for ROS assay.


1238

1239


1240

1241 **Supplementary Figures**


A



B




C




1243 **Figure S1: Cluster annotations and flow cytometry gating.** A, Distinct cell populations are
1244 visualized in UMAP dimensionality reduction plots. Cluster annotation was performed using
1245 canonical markers for each cell type. B, Myocardial neutrophil infiltration was analyzed using
1246 FACS. Gating data are provided. C, number of myocardial Timd4+ resident macrophages was
1247 analyzed using FACS. Gating data are provided.


A




B




C



D



E



1249

1250 **Figure S2: GA promotes a protective and proangiogenic effect on endothelial cells at 1 dpi.**

1251 **A**, A targeted UMAP performed on the subset of endothelial cells. **B**, IPA performed on DEG

1252 comparing GA and Control on the cluster of ECs from the general UMAP (adjusted p -value <0.05).


1253 **C**, Capillary-3 and monocytic clusters accumulate on 4 dpi. **D**, A frequency plot, showing the

1254 relative abundance of endothelial capillaries 1 and 2 at 1 dpi. Capillary-2 was more abundant in

1255 the GA-group, while Capillary-1 was more abundant in the control group. **E**, An unbiased heatmap

1256 of the cluster markers of Capillary-1 and Capillary-2 (adjusted p -value <0.05). **G**, Pathway


1257 analysis using the DAVID tool of the cluster markers for Capillary-1 and Capillary-2.



1259 **Figure S3: GA promotes a biphasic fibroblast response following acute MI in mice.**

1260 **A**, A targeted UMAP of fibroblast subset from the general UMAP showing a distinct cluster
1261 separation of fibroblasts, double-marker monocytes positive also for fibroblast genes, probably
1262 reflecting fibroblast phagocytosis, pericytes and glial cells. **B**, Myofibroblasts as well as the
1263 double-markers monocytes are absent at 1 dpi, and they strongly appear at 4 dpi. **C**, cluster markers
1264 used for annotations. **D**, IPA performed at Days 1 and 4 post injury on the DE genes between GA
1265 and Control of the quiescent fibroblast cluster (adjusted P-value <0.05). While at 1 dpi there is a
1266 strong fibroblast activation, an important contributor for wound healing, at 4 dpi there is a marked
1267 fibroblast silencing, that might reflect a decreased tendency for a fibrotic scar formation.

1268




1270 **Figure S4: Validations for EV isolation**

1271 **A**, Schematic illustration for EV isolation protocol from mouse LV tissue. EVs were purified by
1272 sequential centrifugations at increasing speed up to 100,000 g. Subsequently, EVs were analyzed
1273 to confirm high-purity isolation. **B**, Transmission electron microscopy. Samples were stained with
1274 2% uranyl acetate, revealing membrane-enclosed particles of the anticipated diameter. Scale: 100
1275 nm. **C**, Nanoparticle tracking analysis (NTA) demonstrates a unimodal pick below 200 nm,
1276 consistent with EVs diameter. **D**, Data from proteomic analysis. Common EV-specific protein
1277 markers were detected using mass-spectrometry.

1278


1279



1280

1281 **Figure S5: CD31+SMA+ colocalize in the walls of blood vessels.** A, Representative images of
1282 cardiac sections, at 4 dpi of control (upper row) or GA (lower row). SMA+ areas (*left*) representing
1283 activated fibroblasts, adjacent to arterial blood vessels (circular structures), which are stained
1284 positive also for CD31+ (*right*). Webb-like structures staining solely for CD31+ (*middle*) represent

1285 capillaries. Scale bars: 400 μ m. **B**, A higher magnification of a SMA+CD31+ blood vessel,
 1286 representing an artery. Scale bars: 200 μ m.



1287 **Figure S6: Glatiramer acetate protects cardiomyocytes from stress induced cell death *in vivo***

1288 **and *ex vivo*.** **A**, Representative images of cardiac sections of control and GA treated mice, at 1

1289 dpi, stained for the anti-apoptotic protein, Bcl-X_L. Scale bars: left panels, 1000 μ m; right panels,

1290 250 μ m. **B**, Quantification of %Bcl-X_L area in the LV, normalized to the % of injured area (n=3

1291 for each group). **C**, Quantification of TUNEL positive cells in control and GA treated EVOC (n=3

1292 for each group). **D**, Representative images showing TUNEL positive cells in control and GA treated

1293 EVOC that were exposed to H₂O₂. Scale bars: 500μm. **E**, Higher magnifications of D, showing
1294 CMs positive for TUNEL. Scale bars: 20μm. **F**, Representative images of control and GA treated
1295 EVOC that were exposed to H₂O₂ and stained for the DNA double-strand breaks marker γH2AX.
1296 Scale bars: 500μm. **G**, Higher magnifications of F, showing CMs positive for γH2AX. Scale bars:
1297 20μm. **H**, Quantification of % γH2AX positive cells (n=3 for each group, an average of 550 cells
1298 were counted for each group).

1299

1300

1301

1302

1303

1304

1305

1306

1307

1308

1309

1310

1311

1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332





Fig S7: Models summarizing the pleiotropic beneficial effect of GA on the injured heart.

Illustrations summarizing the effect of GA on multiple cardiac cell types and the crosstalk between them (upper). Black and grey arrows represent direct and indirect effects, respectively. The effect of GA on distinct cell populations is demonstrated by the time course of the cells' participation in the repair process (lower).




1333

1334 **Figure S8: The effects of GA on mouse and human cultured cardiac cells.**

1335 **A**, FACS analysis of P3 cultures used for the *in vitro* experiments reveals negligible amounts of
 1336 immune cells in the cultures. **B**, P3 cultures were treated either with STS alone or with STS + GA.
 1337 Apoptotic CM death was measured by DAPI exclusion assay 18h after the addition of STS. Arrows
 1338 point to dying cells (n_{PBS} = 4, 700 cells; n_{GA} = 5, 1321 cells). Scale bars: 300 μm. **C**, P3 cultures


1339 were treated with FITC-GA for 48h, followed by treatment with 1 μ M H₂O₂ for 2h. DAPI
1340 exclusion assay was performed to determine the levels of cell death, followed by staining with
1341 anti-cTnT (red). Arrowheads point at cTnT+DAPI- cells, representing live CMs in GA-treated
1342 (top) and control cultures (bottom left). Bottom right panel shows the quantification of the fold
1343 change in cTnT+DAPI+ dead CMs between the two groups (n=3 for each group). In total, 1248
1344 cells were counted. Scale bars: 200 μ m. **D**, Representative images of adherent cells at 3h cultures,
1345 showing that most of the cultures contain CFs (vimentin) and ECs (CD31), whereas CMs (cTnT)
1346 are mainly non-adherent at this time point. Scale bars: 750 μ m. **E**, A scheme showing the
1347 experimental design of the conditioned media assay. **F**, DAPI exclusion assay following challenge
1348 with H₂O₂ and treatment with conditioned medium. Quantification of the fold-change in
1349 cTnI+DAPI+ (right) (n=3, 1487 cells). Scale bars: 300 μ m. **G,H**, P3 cultures were treated with
1350 either GA or control for 48h and co-stained with anti-vimentin and anti-pH3 (G) or anti-vimentin
1351 and Ki67 (H). Quantifications show less proliferation of CFs compared to control (n=3 for each
1352 group). In total, 2482 and 3616 cells were counted for GA and PBS, respectively. Scale bars: 200
1353 μ m. **I**, Representative fields (left) and quantification (right) show less proliferation of CFs in GA-
1354 treated cultures derived from human biopsies. Scale bars: 150 μ m. (n = 3, more than >3000 cells
1355 for each group).



1356



1357 **Figure S9: Additional data of the patients that participated in the clinical trial.**

1358 **A**, An extended list of baseline patient characteristics, including demographics, cardiovascular co-
 1359 morbidities and medical therapy. Continuous variables are presented as median and interquartile
 1360 range (IQR), discrete variables as proportions. **B**, Raw values of serum NT-proBNP in the entire
 1361 cohort according to treatment group. NT-proBNP were markedly decreased already at 2 days after
 1362 initiation of GA therapy, while the opposite trend was observed in the control group. 14 days after
 1363 hospitalization, NT-proBNP levels were close to baseline levels in the control group, but still
 1364 markedly lower in the GA-treated group. **C**, Kaplan-Meier curve showing HF hospitalization-free
 1365 in the 3 months following enrollment. Although the number of re-hospitalizations was small (n=3),
 1366 the relative reduction in risk of rehospitalization in the GA-treated group is 64%.



C Human EVs: Common EV-specific markers found in proteomic analysis

Protein Full Name	Protein_Key	Gene	Number of Peptides	% Sequence Coverage
CD5 antigen-like	O43866	CD5L	43	86.167
Fibronectin	P02751	FN1	185	73.96
Actin, cytoplasmic 1	P60709	ACTB	19	58.133
Fibulin-1	P23142	FBLN1	36	56.899
Galectin-3-binding protein	Q08380	LGALS3BP	31	50.598
Monocyte differentiation antigen CD14	P08571	CD14	10	36.533
Lactotransferrin	P02788	LTF	18	34.93
Glyceraldehyde-3-phosphate dehydrogenase	P04406	GAPDH	8	32.239
Scavenger receptor cysteine-rich type 1 protein M130	Q86VB7	CD163	13	14.879



1385 **Figure S10: Proteomic analysis of EV-enriched serum from patients with ADHF**

1386 Proteomic analysis was performed using mass spectrometry on sera from patients that participated
1387 in the clinical trial. The sera were enriched for EVs using ultracentrifugation. **A**, Nanoparticle
1388 tracking analysis, demonstrating that the majority of particles detected are below 200 nm,
1389 averaging 106 nm, characteristic of EVs. **B**, Transmission electron microscopy. Samples were
1390 stained with 2% uranyl acetate, revealing multiple vesicles. Scale: 100 nm. **C**, Proteomic analysis
1391 showing characteristic protein markers for EVs, suggestive of an EV-enriched serum. **D**, Principal
1392 component analysis at three timepoints: baseline, day 2 and 14. At baseline all samples are
1393 scattered randomly. Starting at day 2, a separate cluster of GA-treated patients is apparent,
1394 suggesting a common set of enriched proteins. **E**, A heat map of day 2, generated from DE proteins
1395 in ANOVA, using mean intensities transformed on log₂. Dendrogram showing clustering
1396 according to treatment, and a distinct pattern of proteome expression is evident. **F**, Individual
1397 proteins that were found to be differentially expressed at day 2, shown as fold-change from
1398 baseline levels.

1399

1400

1401

1402

1403